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Abstract
An isolated DNA sequence which regulates the expression of a heterologous gene 
composed of a mouse whey acidic protein promoter having a length of greater than about 
2.4 kb extending upstream from the unique KpnI site in the mouse whey acidic protein 
gene is disclosed. Specifically a mouse whey acidic protein promoter of about 4.1-4.2 kb 
in length extending upstream from the unique KpnI site is preferred. This mouse whey 
acid protein promoter is operably linked to a DNA sequence encoding a heterologous 
polypeptide and used to prepare transgenic non-human mammals expressing the 
heterologous polypeptide in their milk. Particularly efficient expression of both cDNAs 
and genomic DNAs encoding heterologous polypeptides was obtained in transgenic non-
human mammals using this promoter, known as the long whey acidic protein promoter. 
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Claims
What we claim is: 
1. An isolated DNA sequence which regulates the expression of a heterologous gene, 
wherein the DNA sequence comprises a mouse whey acidic protein promoter having a 
length of greater than about the length of the EcoRI-KpnI promoter of the mouse whey 
acidic protein gene. 
2. An isolated DNA sequence according to claim 1, wherein the DNA sequence 
comprises a mouse whey acidic protein promoter having a length of greater than about 
the length of the EcoRI-KpnI promoter of the mouse whey acidic protein gene to less 
than about the length of the Sau3A-KpnI promoter of the mouse whey acidic protein 
gene. 
3. An isolated DNA sequence according to claim 2, wherein the DNA sequence has 
functionally equivalent promoter activity to the mouse whey acidic protein 4.2 kb Sau3A-
KpnI promoter. 
4. An isolated DNA sequence according to claim 1 comprising at least the approximately 
4.2 kb Sau3A-KpnI promoter. 
5. An isolated DNA sequence according to claim 1 comprising at least the NotI-KpnI 
promoter of the mouse whey acidic protein gene. 
6. An isolated DNA sequence according to claim 1, operably linked to a DNA sequence 
encoding a heterologous polypeptide and a 3'-untranslated region from a mammary 
gland-specific gene or 3'-untranslated region active in a mammary gland. 
7. An isolated DNA sequence according to claim 6, wherein said 3'-untranslated region is 
the 1.6 kb fragment of the mouse whey acidic protein gene. 
8. A transgenic non-human mammal containing a DNA sequence stably integrated in its 
genome, wherein said DNA sequence comprises a mouse whey acidic protein promoter 
having a length of greater than about the length of the EcoRI-KpnI promoter of the 
mouse whey acidic protein gene, operably linked to a DNA sequence encoding a 
heterologous polypeptide, whereby said polypeptide is expressed specifically in 
mammary cells of said transgenic mammal and said polypeptide comprises a signal 
peptide, said signal peptide being effective in directing the secretion of said polypeptide 
into the milk of said mammal. 
9. The transgenic non-human mammal of claim 8, wherein said transgenic non-human 
mammal is selected from the group consisting of mice, rats, rabbits, pigs, sheep, goats 
and cows. 
10. The transgenic non-human mammal of claim 9, wherein said mammal is a sheep. 
11. The transgenic non-human mammal of claim 9, wherein said mammal is a goat. 
12. The transgenic non-human mammal of claim 9, wherein said mammal is a cow. 
13. The transgenic non-human mammal of claim 9, wherein said mammal is a pig. 
14. The transgenic non-human mammal of claim 8, wherein said heterologous 
polypeptide is a blood protein. 
15. The transgenic non-human mammal of claim 14, wherein said blood protein is protein 
C, Factor IX, fibrinogen or Factor VIII. 
16. The transgenic non-human mammal of claim 8, wherein said heterologous 
polypeptide is protein C, wherein the activated form of said secreted protein C has an 
enzymatic activity of at least 50% as plasma-derived protein C, and wherein said 
transgenic mammal is selected from the group consisting of mice, rats, rabbits, pigs, 
sheep, goats and cows. 
17. The transgenic non-human mammal of claim 16, wherein said DNA sequence 
encoding the heterologous polypeptide comprises the human protein C gene from 21 
basepairs upstream of the protein C start codon to the NheI site in the 3' end of the 
protein C gene. 
18. The transgenic non-human mammal of claim 8, wherein said DNA sequence 
encoding said heterologous polypeptide further comprises regulatory elements located in 
the non-coding regions of the heterologous protein gene, wherein said regulatory 
elements are at least one of the AUG start codon, donor and acceptor splice signals, the 
secretion peptide, translation termination signal, transcription termination signal, and 
polyadenylation signal. 
19. A process for the production of a heterologous polypeptide in the milk of a transgenic 
non-human mammal, comprising the steps of: 
(A) providing a transgenic non-human mammal whose genome comprises a stably 
integrated DNA sequence comprising a mouse whey acidic promoter having a length of 
greater than about the length of the EcoRI-KpnI promoter of the mouse whey acidic 
protein gene, operably linked to a DNA sequence encoding a heterologous polypeptide 
and a signal peptide, said promoter being specifically active in mammary cells and said 
signal peptide being effective in directing the secretion of said polypeptide into the milk 
of said transgenic mammal; 
(B) producing milk from said transgenic mammal, wherein said milk contains said 
polypeptide; 
(C) collecting said milk; and 
(D) isolating said polypeptide from said milk. 
20. The process of claim 19, wherein said transgenic non-human mammal is selected 
from the group consisting of mice, rats, rabbits, pigs, sheep, goats and cows. 
21. The process of claim 20, wherein said transgenic non-human mammal is a sheep. 
22. The process of claim 20, wherein said transgenic non-human mammal is a goat. 
23. The process of claim 20, wherein said transgenic non-human mammal is a cow. 
24. The mammal of claim 20, wherein said transgenic non-human mammal is a pig. 
25. The process of claim 19, wherein said heterologous polypeptide is a blood protein. 
26. The process of claim 25, wherein said blood protein is protein C, Factor IX, 
fibrinogen or Factor VIII. 
27. The process of claim 19, wherein said heterologous polypeptide is protein C, wherein 
the activated form of said secreted protein C has an enzymatic activity of at least 50% as 
plasma-derived protein C, and wherein said transgenic mammal is selected from the 
group consisting of mice, rats, rabbits, pigs, sheep, goats and cows. 
28. The process of claim 19, wherein said DNA sequence encoding the heterologous 
polypeptide comprises the human protein C gene from 21 basepairs upstream of the 
protein C start codon to the NheI site in the 3' end of the protein C gene. 
29. The process of claim 19, wherein said DNA sequence encoding said heterologous 
polypeptide further comprises regulatory elements located in the non-coding regions of 
the heterologous protein gene, wherein said regulatory elements are at least one of the 
AUG start codon, donor and acceptor splice signals, the secretion peptide, translation 
termination signal, transcription termination signal, and polyadenylation signal. 
Description
The present invention relates to an isolated DNA sequence which regulates the 
expression of a heterologous gene comprising a mouse whey acidic protein (WAP) 
promoter having a length of greater than about 2.4 kb extending upstream from the 
unique KpnI site in the mouse whey acidic protein. The present invention also relates to a 
transgenic non-human mammal containing a DNA sequence stably integrated in its 
genome, wherein the DNA sequence contains the mouse whey acidic protein promoter 
having a length of greater than about 2.4 kb extending upstream from the unique KpnI 
site in the mouse whey acidic protein gene and is operably linked to a DNA sequence 
encoding a heterologous polypeptide and a process of producing the heterologous 
polypeptide in the milk of the transgenic mammal. The DNA sequence can comprise 
cDNA or genomic DNA encoding the heterologous protein. 
The present invention also relates to the production of natural and modified forms of the 
human coagulation factor protein C. In particular, the invention relates to a transgenic 
animal containing, stably incorporated in its genomic DNA, an exogenous gene which is 
expressed in tissue of the animal, specifically in mammary tissue, such that protein C is 
secreted into a body fluid of the animal, particularly into the milk produced by the 
animal. In particular, the invention relates to the production of natural and modified 
forms of protein C in the milk of a transgenic non-human mammal using a DNA 
molecule that comprises, a mouse whey acid protein promoter having a length of greater 
than about 2.4 kb extending upstream from the unique KpnI site in the mouse whey 
acidic protein gene, particularly the upper range of this length, which is herein referred to 
as the long whey acidic protein (WAP) promoter fragment and a cDNA or genomic DNA 
encoding human protein C. The long whey acidic protein promoter fragment also can be 
used to express high levels of other genes in cells, such as mammary cells of transgenic 
non-human mammals. 
BACKGROUND OF THE INVENTION 
Protein C is an important component of the coagulation system that has strong 
anticoagulant activity. In its active form it is a serine protease that proteolytically 
inactivates Factors Va and VIIIa. 
Human protein C (hPC) is a 62 kD, disulfide-linked heterodimer consisting of a 25 kD 
light chain and a 41 kD heavy chain which circulates as an inactive zymogen in plasma. 
At the endothelial cell surface it is activated to activated protein C (APC) by limited 
thrombin proteolysis in the presence of thrombomodulin; cleavage of an Arg-Leu bond in 
the amino terminal portion of the heavy chain releases a 12 amino acid peptide. See 
generally Gardiner & Griffin in PROGRESS IN HEMATOLOGY, Vol. XIII at page 265-
278 (Brown, Grune and Stratton, Inc. 1983). 
Several regions of the molecule have important implications for function as an 
anticoagulant in the regulation of hemostasis. The amino terminal portion of the light 
chain contains the nine y-carboxyglutamic acid (Gla) residues required for calcium-
dependent membrane binding and functional activation. Another post-translational 
modification is .beta.-hydroxylation of aspartic acid reside 71, possibly required for 
calcium-dependent membrane binding which is independent of the binding activity of the 
Gla regions. 
There are a variety of clinical situations for which protein C may prove beneficial. It may 
serve as replacement therapy in homozygous deficient infants suffering from purpura 
fulminans neonatalis. Other conditions include patients with a previous history of 
warfarin-induced skin necrosis who must have additional warfarin therapy, heparin-
induced thrombocytopenia, septic shock for prevention of intravascular coagulation and 
organ damage, and for fibrinolytic therapy, as protein C can protect tPA from plasma 
inhibitor proteins. Table 1 represents one estimate of the number of individual cases of 
several clinical syndromes which might be treated by purified protein C. Because there 
has not been sufficient material available from plasma for clinical trials until recently, 
these data are necessarily based on an incomplete assessment of the therapeutic potential 
for protein C. 
                             TABLE 1
          PARTIAL ESTIMATE OF U.S. CLINICAL REQUIREMENTS
              FOR PROTEIN C AND ACTIVATED PROTEIN C
                          Estimated
                          Dose (mg)
                             Per      # Treatments   Total U.S.
        Indication        Treatment    Per Year      Req. (Kg)
        Septic Shock        5-50        120,000      0.6-6.0
        Thrombolytic       10-100       800,000        8-80
        Therapy**
        Hip Replacement    10-100       200,000        2-20
        Homozygous            3       100 .times. 365*      0.10
        Deficient
        Heterozygous         50          1,000         0.05
        Deficient
        Total                                       10.8-106.2
    *100 individuals in U.S. .times. 365 treatment/year
    **Referes to the use of APC, following thrombolytic therapy, to 
prevent the
     reformation of blood clots.
The gene for human protein C has been cloned and sequenced, as has bovine protein C 
gene. See Forster et al., Proc. Nat'l Acad. Sci. USA 82: 4673 (1985); U.S. Pat. No. 
4,775,624. It is synthesized as an inactive precursor that undergoes several proteolytic 
events during the processes of secretion and activation. First, a signal sequence as 
proteolytically removed upon secretion. A second proteolytic event removes the 
dipeptide lys156 arg157, producing the inactive zymogen, a two chain disulfide bridged 
protein, consisting of a light chain of 155 amino acids and a heavy chain of 262 amino 
acids. The zymogen is activated by a final proteolytic event that removes residues 158-
169, yielding active protein C, a serine protease with potent anticoagulant activity. 
Beckmann et al., Nucleic Acids Res. 13: 5233 (1985). 
In addition to proteolytic processing, human protein C undergoes several post-translation 
modifications. Perhaps most salient among these modifications is the .gamma.-
carboxylation of the first nine glutamic acid residues in protein C, by a vitamin K 
dependent enzyme. DiScipio & Davie, Biochemistry 18: 899 (1979). Gamma-
carboxylation is required for anticoagulant activity, and is associated with Ca.sup.2+ -
dependent membrane binding. The anticoagulant activity of protein C varies directly with 
the extent of .gamma.-carboxylation, and the highest levels of activity are achieved only 
when .gamma.-carboxylation of the sixth and seventh glutamic acid residues is effected. 
Zhang & Castellino, Biochemistry 29: 10829 (1990). 
Protein C is also post-translationally modified by .beta.-hydroxylation of aspartic acid 71. 
Drakenberg et al., Proc. Nat'l Acad. Sci. USA 80: 1802 (1983). Beta-hydroxylation may 
be important to protein C activity. Although its function is not known it has been 
suggested that it may be involved in .gamma.-carboxyglutamic acid independent 
Ca.sup.2+ binding, and it may be required for full anti-coagulant activity. 
Human protein C is also glycosylated. Kisiel, J. Clin. Invest. 64: 761 (1979). It contains 
four potential N-linked glycosylation sites, located at Asn97, Asn248, Asn313 and 
Asn329. The first three signals match the consensus Asn-X-Ser/Thr glycosylation 
sequences, and are actively glycosylated. There is an atypical glycosylation signal at 
Asn329, Asn-X-Cys-Ser. The Asn329 signal is glycosylated in bovine protein C, but it is 
not yet known if Asn329 is glycosylated in human protein C. Miletich et al., J. Biol. 
Chem. 265: 11397 (1990). The pattern and extent of glycosylation can alter the 
physiological activity of protein C. 
Until recently, human protein C for experimental and therapeutic use was obtained 
exclusively from human plasma. Unfortunately, the quantity of protein that can be 
obtained from human serum is limited. Furthermore, products derived from human serum 
pose difficulties of reliability, purity and safety. 
The expression of therapeutic proteins by recombinant DNA technology is an attractive 
alternative to plasma production of protein C, in that it eliminates the risk of potential 
contamination with blood-borne viruses and theoretically provides an unlimited supply of 
product. But the complexity of the post-translational modifications, as discussed above, 
has rendered problematic the production of commercially useable amounts of suitably 
active protein C by expression in a heterologous host. 
In fact, it has not been possible to produce vitamin K-dependent proteins like protein C at 
sufficiently high levels in an active form, despite efforts to do so using a variety of 
expression systems. See Grinnell et al. in Volume 11 of ADVANCES IN APPLIED 
BIOTECHNOLOGY SERIES, Chapter 3 (Gulf Publishing Co.). In particular, any 
prospect for expressing protein C in mammary glands of a transgenic animal and 
secreting the protein into milk, see, e.g., U.S. Pat. No. 4,873,316 (1989), is clouded by 
the fact that protein C is normally synthesized in the liver. Even HepG2 cell lines derived 
from human liver produce aberrant forms of protein C. Marlar & Fair (1985). 
In this regard, it has been observed that a mouse mammary epithelial cell line (C-127) 
transfected with a bovine papilloma virus (BPV) vector bearing the cDNA for human 
protein C expressed protein C that was only 30-40% active. Further analysis revealed that 
the protein C contained diminished levels of .gamma.-carboxyglutamic acid and little, if 
any, .beta.-hydroxyaspartic acid. Suttie et al., Thrombosis Res. 44: 129 (1986). These 
experiments indicate that mouse mammary epithelial cells cannot perform all of the post-
translational modifications necessary for obtaining suitably active protein C, which in 
turn casts doubt on the likelihood of obtaining such protein C from the milk of a 
transgenic mammal. 
SUMMARY OF THE INVENTION 
It is an object of the present invention to obtain and use an isolated DNA sequence which 
regulates the expression of a heterologous gene, wherein the DNA sequence comprises of 
a mouse whey acidic protein promoter having a length of greater than about 2.4 kb 
extending upstream from the unique KpnI site in the mouse whey acidic protein gene. 
The mouse whey acidic protein promoter of the present invention is more specifically an 
isolated DNA sequence comprising a mouse whey acidic protein promoter having a 
length of greater than about 2.4 kb to less than about 4.2 kb. The isolated DNA sequence 
may also encompass mouse whey acidic protein promoters that are functionally 
equivalent to the promoter activity of the mouse whey acidic 4.2 kb Sau3A-Kpn1 
promoter. 
It also is an object of the present invention to obtain and use an isolated DNA sequence 
comprising a mouse whey acidic protein promoter comprising at least the approximately 
mouse whey acidic protein 4.2 kb Sau3A-Kpn1 promoter. 
It is a further object of the present invention to obtain and use an isolated DNA sequence 
comprising a mouse whey acidic protein promoter comprising the NotI-Kpn1 promoter of 
the mouse whey acidic protein gene. 
It is an additional object of the present invention to operably link any of the disclosed 
mouse whey acidic protein promoters to a DNA sequence encoding a heterologous 
polypeptide and a 3'-untranslated region from a mammary gland-specific gene or a 3'-
untranslated region active in a mammary gland. This 3'-untranslated region is preferably 
the 1.6 kb fragment of the mouse whey acidic protein gene. The DNA sequence encoding 
a heterologous polypeptide is intended to be any DNA sequence that is known and 
available to persons skilled in the art. The DNA sequence preferably encodes a blood 
protein or plasma protein, and more preferably encodes such blood proteins as protein C, 
Factor IX, fibrinogen, Factor VIII, thrombin, von Willebrand's factor, albumin, and 
.alpha.1-antitrypsin, as well as growth factors and antibodies. 
It also is an object of the present invention to produce a transgenic non-human mammal 
containing a DNA sequence stably integrated in its genome, wherein the DNA sequence 
comprises a mouse whey acidic protein promoter having a length of greater than about 
2.4 kb extending upstream from the unique KpnI site in the mouse whey acidic protein 
gene, operably linked to a DNA sequence encoding a heterologous polypeptide, whereby 
the polypeptide is expressed specifically in mammary cells of the transgenic mammal and 
the polypeptide comprises a signal peptide that is effective in directing the secretion of 
the polypeptide into the milk of said mammal. 
In a highly preferred embodiment the promoter comprises substantially the 5' 4.2 kb 
Sau3A-Kpn1 promoter fragment of the mouse whey acidic protein gene, or a variant 
thereof. This 4.2 kb Sau3A-KpnI promoter may be contained in a longer DNA sequence 
to include polylinkers that will facilitate the construction of expression vectors, such as 
for example, introducing a NotI cloning site upstream from the Sau3A site. 
In another aspect in a preferred embodiment the DNA sequence encoding a polypeptide 
having human protein C activity comprises portions of the non-coding regions of the 
human protein C gene. In a particularly preferred embodiment, the DNA sequence gene 
comprises substantially the human protein C gene from 21 basepairs upstream of the 
protein C start codon to the NheI site in the 3' end of the protein C gene, or a variant 
thereof is among the most highly preferred. 
In a particularly preferred embodiment, the exogenous DNA sequence comprises a DNA 
sequence consisting essentially of the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the 
mouse whey acidic protein promoter ligated directly or by a linker to a fragment of the 
human protein C gene beginning 21 basepairs upstream of the protein C start codon and 
ending at the Nhel site in the 3' end of the protein C gene. 
In accordance with another aspect of the present invention, there has been provided a 
process for the production of protein C, comprising the steps of (A) providing a 
transgenic mammal characterized by an exogenous DNA sequence stably integrated in its 
genome, wherein the exogenous DNA sequence comprises a promoter operably linked to 
a DNA sequence encoding a polypeptide having protein C activity and a signal peptide, 
the promoter being specifically active in mammary cells and the signal peptide being 
effective in directing the secretion of the protein C into the milk of the transgenic 
mammal; (B) producing milk from the transgenic mammal; (C) collecting the milk; and 
(D) isolating the polypeptide from the milk. 
It is therefore an object of the present invention to provide a transgenic animal which 
produces in its milk recombinant protein C that comprises a significantly higher 
percentage of active protein than has been achieved heretofore. 
It is another object of the present invention to provide a process for producing protein C 
in commercially useable amounts, by means of a transgenic mammal. 
In accomplishing the foregoing objects, there has been provided, in accordance with one 
aspect of the present invention, a transgenic mammal containing an exogenous DNA 
sequence stably integrated in its genome, wherein the exogenous DNA sequence 
comprises a promoter operably linked to a DNA sequence encoding a polypeptide having 
protein C activity and a signal peptide, wherein the promoter is specifically active in 
mammary cells, particularly mammary epithelial cells, and the signal peptide is effective 
in directing the secretion of the protein C into the milk of the transgenic mammal. 
Additionally, in a preferred embodiment the DNA sequence encoding a polypeptide 
having human protein C activity comprises portions of the non-coding regions of the 
human protein C gene. In a particularly preferred embodiment of this type the DNA 
sequence gene comprises substantially the human protein C gene from 21 basepairs 
upstream of the protein C start codon to the NheI site in the 3' end of the protein C gene, 
or a variant thereof is among the most highly preferred. 
In addition, is certain a particularly preferred embodiment, the exogenous DNA sequence 
comprises a DNA sequence consisting essentially of the 5' 4.2 kb Sau3A-Kpn1 promoter 
fragment of the mouse whey acidic protein promoter ligated directly or by a linker to a 
fragment of the human protein C gene beginning 21 basepairs upstream of the protein C 
start codon and ending at the NheI site in the 3' end of the protein C gene. 
In accordance with still another aspect of the present invention, a process has been 
provided for producing transgenic animals, comprising the steps of (A) providing a 
mixture containing a genetic construct; (B) subjecting the mixture to anion-exchange 
high performance liquid chromatography to obtain purified genetic construct; and 
thereafter (C) microinjecting an aqueous buffer solution containing the purified genetic 
construct into an animal embryo. In a preferred embodiment, step (B) comprises applying 
the mixture to an anion-exchange high performance liquid chromatography column, 
eluting the genetic construct from the column, and then subjecting the genetic construct 
to a second anion-exchange high performance liquid chromatography. 
In a preferred embodiment of this aspect of the invention, the double-stranded DNA is 
selected from the group consisting of a double-stranded DNA comprising substantially 
the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the mouse whey acidic protein promoter, 
a double-stranded DNA comprising substantially a fragment of the human protein C gene 
beginning 21 basepairs upstream of the protein C start codon and ending at the NheI site 
in the 3' end of the protein C gene, and a double-stranded DNA comprising a DNA 
sequence consisting essentially of the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the 
mouse whey acidic protein promoter ligated directly or by a linker to a fragment of the 
human protein C gene beginning 21 basepairs upstream of the protein C start codon and 
ending at the Nhel site in the 3' end of the protein C gene. 
In accordance with yet another aspect of the invention, there has been provided a process 
for the production of a polypeptide in the milk of a transgenic non-human mammal, 
comprising the steps of providing a non-human transgenic mammal characterized by an 
exogenous DNA sequence stably integrated in its genome, wherein said exogenous DNA 
sequence comprises substantially the 5' 4.2 kb Sau3A-Kpn1 promoter of the mouse whey 
acidic protein gene, or a variant thereof, operably linked to a DNA sequence encoding 
said polypeptide and a signal peptide, said promoter being specifically active in 
mammary cells and said signal peptide being effective in directing the secretion of said 
polypeptide into the milk of said transgenic mammal; producing milk from said 
transgenic mammal; collecting said milk; and isolating said polypeptide from said milk. 
In a particularly preferred embodiment of this aspect of the invention, the exogenous 
DNA sequence comprises the 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the mouse 
whey acidic protein promoter. 
In accordance with yet another aspect of the invention there has been provided a 
transgenic non-human mammal containing an exogenous DNA sequence stably 
integrated in its genome, wherein the exogenous DNA sequence comprises substantially 
the 4.2 kb Sau3A-Kpn1 whey acidic protein promoter fragment, or a variant thereof, 
operably linked to a DNA encoding a polypeptide whereby the protein is expressed 
specifically in mammary cells of the transgenic mammal and the protein comprises a 
signal peptide, the peptide being effective in directing the secretion of the protein into the 
milk of said mammal. In a particularly preferred embodiment of this aspect of the 
invention, the exogenous DNA sequence comprises the 5' 4.2 kb Sau3A-Kpn1 promoter 
fragment of the mouse whey acidic protein promoter. 
In certain preferred embodiments of various aspects of the invention, the transgenic 
mammal is mouse, rabbit, pig, sheep or goat. In some most highly preferred embodiments
the animal is pig or sheep. 
Other objects, features and advantages of the present invention will become apparent 
from the following detailed description. It should be understood, however, that the 
detailed description and the specific examples, while indicating preferred embodiments 
of the invention, are given by way of illustration only, since various changes and 
modifications within the spirit and scope of the invention will become apparent to those 
skilled in the art from this detailed description. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a schematic diagram representing WAPpCI, a construct which contains cDNA 
encoding human protein C inserted into an intact murine whey acidic protein (WAP) 
gene at the unique Kpn1 site. 
FIG. 2 is a schematic representation of polymerase chain reaction (PCR) primer pairs 
useful to detect WAP-protein C DNAs in transgenic animals. 
FIG. 3 is a graph that shows the results of an enzyme linked immunosorbent assay 
(ELISA) of human protein C in milk obtained from a transgenic mouse. 
FIG. 4 is a graph that shows the results of an APTT assay to determine human protein C 
anti-coagulant activity in whey obtained from a transgenic mouse. 
FIG. 5 is a graph that shows the results of Ca.sup.2+ -dependent and Ca.sup.2+ -
independent light chain capture ELISAs which demonstrate that the .gamma.-
carboxyglutamic acid in human protein C in whey from transgenic mouse Y52 is similar 
to that in protein C derived from human serum. 
FIG. 6 is a schematic diagram representing a highly preferred murine WAP-human 
protein C construct. In this construct, a 4.2 kb 5' murine whey acidic protein promoter 
fragment is linked to a 9.4 kb genomic fragment encoding human protein C which 
includes the 400 bp extending from the end of exon VIII to the NheI site in the 3' end of 
the human protein C gene. The sequence of the WAP--hPC junction is shown above the 
schematic diagram. 
FIG. 7 is a photograph showing the results of western analyses of human protein C 
production in the milk of transgenic animals. Panel A shows the proteins in whey 
samples resolved by PAGE under reducing conditions and visualized by silver staining. 
Panel B shows the proteins detected by anti-human protein C antibodies in a western blot 
of an identical gel, visualized by chemiluminescence. Lanes were loaded with 
approximately 5 .mu.g of protein. Lanes 1 through 6 contained, respectively, samples 
from transgenic mice 5.4, 6.4, 4.2.10, 5.2.12, 7.2.2 and 7.5.4. Lane 7 contained a sample 
from a non-transgenic mouse. Lane 8 contained purified human protein C. "SC"--single 
chain hPC, "HC"--heavy chain forms of hPC, "LC"--light chain hPC. 
FIG. 8 shows the amidolytic activity in samples of whey from transgenic mice. Panel A 
shows amidolytic activity of whey proteins resolved by PAGE under native conditions. 
Panel B shows the proteins detected by anti-hPC antibodies in a western blot of an 
identical gel, visualized using 4-chloro-1-naphthol. Lanes were loaded with 
approximately 50 .mu.g of protein. Lane 1 contained purified human protein C. Lane 2 
contained a sample form a non-transgenic mouse. Lanes 3 through 8 contained, 
respectively, samples from transgenic mice 7.5.4, 7.2.2, 5.2.12, 4.2.10, 6.4 and 5.4. 
FIG. 9 shows the nucleotide sequence SEQ ID NO:1 of the WAP gene promoter 
fragment from the C57B/6 mouse strain. The sequence from the Sau3A site to the KpnI 
site is shown. 
FIGS. 10A-10D schematically depict the construction of a chimeric Factor IX (FIX) 
construct containing the short WAP promoter. Specifically, FIG. 10A shows the 
construction of pWAP4. FIG. 10B shows the production of pUCFIX. FIG. 10C shows the 
introduction of human FIX cDNA into pWAP4. FIG. 10D shows the production of 
pUCWAPFIX. FIX cDNA was modified by PCR in order to introduce KpnI sites on the 
3' and 5' ends. Using FIX cDNA as a template, PCR primers humFIX5'KpnI and 
humFIX3'KpnI, as shown in Table 6, below, were used to produce FIX cDNA with KpnI 
sites on both ends. Modified cDNA may be easily introduced into a "cassette vector" for 
constructing a chimeric gene.
FIGS. 11A-11C show the production of the pUCWAP6 "cassette vector." Specifically, 
FIG. 11A shows the production of pUCNotI. FIG. 11B shows the production of of 
pUCWAP5 and the production of a fragment that contains the pUCNotI vector sequence 
flanked by mWAP3'UTR. FIG. 11C shows the production of pUCWAP6. 
FIG. 12 shows the production of pUCWAP6FIX. 
FIG. 13 shows the pUCWAP5 cassette vector containing the WAP fragment of 
pUCWAP4 with added Not I linkers. 
FIG. 14 shows the pUCWAP5 incorporating a polynucleotide encoding the FIB A.alpha. 
1 chain. 
FIG. 15 shows the pUCWAP5 incorporating a polynucleotide encoding the FIB B.beta. 1 
chain. 
FIG. 16 shows the pUCWAP5 plasmid incorporating a polynucleotide encoding the FIB 
.gamma. 1 chain. 
DETAILED DESCRIPTION OF THE INVENTION 
Notwithstanding past failures to express heterologous proteins, such as recombinant 
protein C with suitably high activity in several different expression systems, including 
transformed mammary cells, it has been discovered that recombinant protein C 
characterized by a high percentage of active protein can be obtained in the milk of 
transgenic animals that incorporate DNAs according to the present invention. Transgenic 
animals of the present invention are produced by introducing into developing embryos 
DNA that encodes protein C, such that the DNA is stably incorporated in the DNA of 
germ line cells of the mature animal and inherited in normal, mendelian fashion. In 
accordance with the invention, DNAs can be introduced into embryos by a variety of 
means to produce transgenic animals. For instance, totipotent or pluripotent stem cells 
can be transformed by microinjection, calcium phosphate mediated precipitation, 
liposome fusion, retroviral infection or by other means. The transformed cells can then be 
introduced into embryos and incorporated therein to form transgenic animals. In a 
preferred method, developing embryos can be infected with retroviral vectors and 
transgenic animals can be formed from the infected embryos. In the most preferred 
method, however, the DNAs of the invention are injected into embryos, preferably at the 
single-cell stage, which are allowed to develop into mature transgenic animals. 
Suitable protein C-encoding DNA used for producing transgenic animals in this fashion 
can be obtained using human liver tissue as a source for cloning the hPC gene. The DNA 
coding for protein C can be fused, in proper reading frame, with appropriate regulatory 
signals, as described in greater detail below, to produce a genetic construct which is then 
amplified, for example, by propagation in a bacterial vector, according to conventional 
practice. 
The amplified construct is thereafter excised from the vector and purified for use in 
microinjection. The purification is preferably accomplished by means of high 
performance liquid chromatography (HPLC), which rids the construct of contamination 
from the bacterial vector and from polysaccharides typically present when other 
techniques, such as conventional agarose electroelution, are used. The preferred HPLC 
method entails sorbing the construct onto an anion-exchange HPLC support and 
selectively eluting the construct from the support, preferably with an aqueous sodium 
chloride solution, thereby to eliminate contamination from the vector. (Elution may be 
effected by other means, such as a pH gradient.) Alternatively but less preferably, the 
excised construct can be purified by ultracentrifugation through an aqueous sucrose 
gradient. 
Since it is preferable that the construct have the minimum amount of impurities, more 
than one cycle of HPLC or other purification is advantageous. In particular, the use of 
HPLC-purified DNA for microinjection, as described above, allows for remarkably high 
transformation frequencies, on the order of 20% or more in both mice and pigs. All 
lactating animals, that is, all mammals, are suitable for use according to the present 
invention. Preferred mammals include mice, rats, rabbits, pigs, sheep, goats and cows. 
More particularly, mice, pigs, sheep, goats and cows are preferred. Most preferred at 
present are mice, pigs and sheep. 
DNA constructs useful in the present invention provide a DNA sequence encoding 
protein C operably linked to all the cis-acting signals necessary for mammary tissue 
specific expression of protein C, post-translational modification of protein C, secretion of 
protein C into milk, and full biological activity of protein C. 
DNAs useful in the invention include genomic or complementary DNAs that encode 
naturally occurring protein C. In a preferred embodiment DNAs encoding human protein 
C are employed, including cDNA and genomic DNAs. DNAs encoding protein C from 
other species may also be used, such as the protein C encoded by rats, pigs, sheep, cows 
and chimpanzees. 
In a particularly preferred embodiment, human genomic DNAs encoding protein C are 
employed. Among the most highly preferred human genomic DNAs is the fragment of 
the human protein C gene beginning 21 basepairs upstream of the protein C start codon 
and ending at the NheI site in the 3' end of the protein C gene. This fragment, 
approximately 9.4 kb long, contains regulatory elements that engender high expression of 
human protein C in the milk of non-human transgenic mammals. Some of these 
regulatory elements are the AUG start codon, donor and acceptor splice signals, the 
secretion peptide, and the translation termination, transcription termination and 
polyadenylation signals. 
It will be appreciated that there may be additional regulatory elements in the fragment 
that aid the production of transgenic non-human mammals that express high levels of 
protein C in their milk. Some of these signals may be transcription or translation control 
signals, or those associated with transport out of the cell. Other signals may play a role in 
efficient chromosomal integration or stability of the integrated DNA. Various regions of 
the fragment may contain such signals, such as the region between the end of exon VIII 
and the NheI site in the 3' end of the protein C gene. 
It will be readily appreciated that deletional and other mutational techniques may be 
employed to elucidate further all the signals in this fragment that confer high levels of 
protein C expression in the milk of transgenic animals. 
It will also be appreciated that the 9.4 kb protein C fragment described above can be 
modified using recombinant DNA techniques in many ways. 3' or 5' portions of the 
protein C gene can be added, or a few bases at either end may be removed. Introns can be 
removed or added. Portions of one or more introns can be deleted. Additional DNA can 
be inserted into them. The sequences of the introns can be altered. Exons can be modified 
in accordance with the discussion of modified protein C molecules set forth below. Most 
such modified forms of the preferred genomic protein C fragment will not be 
significantly changed in their ability in transgenic animals to engender the production of 
milk-born protein C. Thus, these substantially similar fragments will be equivalent in the 
invention to the particularly disclosed 9.4 kb fragment of human protein C that begins 21 
basepairs upstream of the protein C start codon and ends at the NheI site in the 3' end of 
the protein C gene. 
Modified protein C sequences also can be employed in the present invention. Useful 
modifications in this context include but are not limited to those that alter the post-
translational processing of protein C, that alter the size of protein C, that fuse protein C or 
portions thereof to portions of another protein, or that alter the active site of protein C. 
Preferred modifications include those that provide an activated protein C and those that 
provide for activation of protein C in the absence of thrombomodulin. In a preferred 
embodiment, modified forms of human protein C are employed. 
Such modifications can be introduced into protein C by techniques well known to the art, 
such as the synthesis of modified genes by ligation of overlapping oligonucleotide, and 
by introducing mutations directly into cloned genes, as by oligonucleotide mediated 
mutagenesis, inter alia. The cis-acting regulatory regions useful in the invention include 
the promoter used to drive expression of the protein C gene. Promoters useful in the 
invention are active in mammary tissue. Particularly useful are promoters that are 
specifically active in mammary tissue, i.e., are more active in mammary tissue than in 
other tissues under physiological conditions where milk is synthesized. Most preferred 
are promoters that are both specific to and efficient in mammary tissue. By "efficient" it 
is meant that the promoters are strong promoters in mammary tissue that can support the 
synthesis of large amounts of protein for secretion into milk. 
Among such promoters, the casein, lactalbumin and lactoglobulin promoters are 
preferred, including, but not limited to the .alpha.-, .beta.- and .gamma.-casein promoters 
and the .alpha.-lactalbumin and .beta.-lactoglobulin promoters. Preferred among the 
promoters are those from rodent (murine and rat), pigs and sheep, especially the rat 
.beta.-casein promoter and the sheep .beta.-lactoglobulin promoter. The most preferred 
promoters are those that regulate a whey acidic protein (WAP) gene, and the most 
preferred WAP promoter is the murine WAP promoter. 
A most highly preferred promoter is a mouse whey acidic protein promoter having a 
length of greater than about 2.4 kb extending upstream from the unique KpnI site in the 
mouse whey acidic protein gene. A mouse whey acidic protein promoter with a length of 
approximately 2.4 kb is known as the short WAP promoter. The present invention refers 
to the short WAP promoter in various locations and in the figures of the present invention 
as having a length of approximately 2.4-2.6 kb as identified by gel electrophoresis. As is 
known by persons skilled in the art, this technique provides an approximation of fragment 
sizes. The size of 2.4-2.6 kb was determined in 1982 and based on methods of gel 
electrophoresis available at that time. The methods were crude and a band of 2.5 kb, for 
example, could mean that the fragment is somewhere between 2.3-2.7 kb in size. This 
short WAP promoter is composed of the EcoRI-KpnI fragment of the mouse whey acid 
protein promoter. It is now known as a result of nucleotide sequencing by techniques well 
known to persons skilled in the art that the short WAP promoter is 2410 basepairs in 
length, and thus the approximate length of 2.4 kb is the correct size designation. This 
short WAP sequence has been deposited with GenBank and has the Accession No. 
U38816. Thus, the present invention is intended to encompass a WAP promoter having 
more than 2410 basepairs. Additionally, the short WAP promoter is described in Gordon 
et al., Bio/Technology 5, 1183-1187 (1987), as having a length of 2.6 kb. This 
publication is incorporated in its entirety by reference. Thus, the present invention also 
encompasses a WAP promoter having a length greater than 2.6 kb, as determined by the 
methods of Gordon et al. 
It is the object of the present invention to encompass a mouse whey acidic protein 
promoter having a length of greater than the short WAP promoter of 2.4 kb in length with 
this long WAP promoter being responsible for the expression of a heterologous 
polypeptide at similar or higher levels to that of the Sau3A-KpnI promoter. The promoter 
expression levels are measureable by persons skilled in the art given the guidance 
provided in the present application. 
A most highly preferred promoter is the 4.2 kb Sau3A-Kpn1 promoter fragment of the 
mouse whey acidic protein promoter. This promoter fragment is described in detail and 
the sequence is provided in Paleyanda et al., Transgenic Research 3: 335-343 (1994), 
incorporated herein to disclose inherent properties of the Sau3A-KpnI promoter. The 
Paleyanda et al. publication refers to this promoter fragment as having a length of 4.1 kb. 
Again as discussed above, the length as determined by gel electrophoresis is approximate. 
It is now known as a result of nucleotide sequencing by techniques well known to 
persons skilled in the art that this Sau3A-KpnI WAP promoter is 4122 basepairs in 
length, and thus the approximate length of 4.1 to 4.2 kb is the correct size designation. 
This long WAP sequence was deposited on May 24, 1994 with GenBank and has the 
Accession No. X79437. 
The Sau3A-KpnI fragment is also contained within the NotI-KpnI fragment as shown in 
FIG. 6. This NotI-KpnI fragment containing the Sau3A-KpnI fragment is used to prepare 
expression constructs for microinjection for the preparation of transgenic mammals. The 
Sau3A-KpnI fragment is modified at the Sau3A end by the addition of a NotI site to 
facilitate the preparation of expression vectors. In various locations in the present 
application, the plasmid pUCWAP6 contains a long WAP promoter with an approximate 
length of 4.1 kb bounded by NotI and KpnI restrictions sites. The NotI site is part of the 
plasmid. The NotI-KpnI promoter fragment is 4136 basepairs in length. The present 
invention is intended to encompass long WAP promoters with these approximate lengths. 
It has been found that this fragment is highly efficacious in directing the production of 
high levels of a protein in the milk of a transgenic animal. In the case of human protein C 
this mouse whey acidic protein promoter fragment has engendered the production of 
active protein C in the milk of transgenic animals in concentrations above 4 mg/ml (by 
polyclonal ELISA). 
It also has been found that this long WAP promoter fragment is highly efficacious in 
directing the production of high levels of polypeptides, particularly blood proteins, such 
as Factor IX, Factor VIII, human fibrinogen, thrombin, and von Willebrand's factor in the 
milk of a transgenic animal. In the case of Factor IX, transgenic founder animals have 
expressed cDNA encoding Factor IX at levels as high as 1500 .mu.g/ml. In the case of 
human fibrinogen, this mouse whey acidic protein promoter fragment has engendered the 
production of active fibrinogen in the milk of transgenic animals in concentrations of 
about 700 .mu.g/ml. See Butler et al., Thrombosis and Haemostasis, 78 (1), 537-542 
(1997), herein incorporated in its entirety by reference. 
It will be readily appreciated, as for the 9.4 kb protein C genomic DNA discussed above, 
the 4.2 kb Sau3A-Kpn1 whey acidic protein promoter fragment can be modified by 
recombinant DNA techniques readily available to those of ordinary skill in the art. Thus, 
the fragment can be shortened, keeping in mind that the 2.4 kb 5' WAP promoter 
fragment gives rise to very much lower yields. It can be lengthened to include more of 
the whey acid protein promoter region or other portions of the whey acid protein gene. 
Portions can be removed, and DNA can be inserted into the fragment. Internal bases can 
be altered. In the majority of cases these alternatives will not affect the ability of this 
promoter fragment to induce very high levels of expression. Fragments modified in this 
way, giving the expected high yields of protein in transgenic milk, are substantially 
similar variants of the 4.2 kb 5' promoter fragment. They also are useful in the present 
invention and are functionally equivalent in this respect to the 4.2 kb Sau3A-Kpn1 whey 
acidic protein promoter fragment itself. 
Also important to the invention are the signal sequences that direct secretion of protein 
into the milk of the transgenic animal. In this regard, both endogenous and heterologous 
signal sequences are useful in the invention. Generally, the signal peptides of proteins 
normally secreted into milk are useful in the invention. The signal sequences of proteins 
that occur in high concentration in milk are particularly preferred, such as the signal 
peptides of the caseins, lactalbumins and lactoglobulins, including, but not limited to the 
signal peptides of the .alpha.-, .beta.- and .gamma.-caseins and .alpha.-lactalbumin and 
.beta.-lactoglobulin. More particularly, the signal sequence of whey acidic protein is 
preferred, most particularly the signal sequence of the murine whey acidic protein. 
Also particularly preferred are the signal peptides of secreted coagulation factors. 
Especially preferred in this regard are the signal peptides of protein C, and t-PA. Most 
especially preferred is the secretion signal of human protein C. 
Among the sequences that regulate transcription that are useful in the invention, in 
addition to the promoter sequences discussed above, are enhancers, splice signals, 
transcription termination signals and polyadenylation sites, among others. Particularly 
useful regulatory sequences increase the efficiency of mammary cell specific expression 
of protein C in transgenic animals. Especially useful in this regard are the other 
transcription regulatory sequences of genes expressed at high levels in mammary cells, 
such as the .alpha.-, .beta.-and .gamma.-casein genes and the .alpha.-lactalbumin and 
.beta.-lactoglobulin genes mentioned above. Preferred sources for regulatory sequences in 
this regard are rodents (mice and rats), pigs and sheep. Exemplary of preferred regulatory 
sequences are those associated with the rat .beta.-casein gene and the sheep .beta.-
lactoglobulin gene, respectively. The regulatory sequences most preferred for use in the 
present invention are those associated with whey acidic protein genes. Particularly 
preferred in this context are regulatory sequences of the murine whey acidic protein. 
Among the sequences that regulate translation, in addition to the signal sequences 
discussed above, are ribosome binding sites and sequences that augment the stability the 
protein C mRNA. Especially useful are the translation regulatory sequences of genes 
expressed at high levels in mammary cells. For instance, the regulatory sequences of the 
.alpha.-, .beta.- and .gamma.-casein genes and the .alpha.-lactalbumin and .beta.-
lactoglobulin genes are preferred, especially those from rodents (mice and rats), pigs and 
sheep. Even more particularly preferred are the regulatory sequences of rat .beta.-casein 
and the sheep .beta.-lactoglobulin genes. The most preferred translational regulatory 
sequences of the invention are those of the whey acidic protein and the protein C genes. 
And the most particularly preferred regulatory sequences are those of the murine whey 
acidic protein and human protein C, including human genomic protein C and human 
protein C cDNA constructs, and including human protein C cDNA constructs that contain 
intron sequences. Among these, the most highly preferred are the regulatory sequences of 
the human protein C gene in the region beginning 21 basepairs upstream of the protein C 
start codon and ending at the NheI site in the 3' end of the protein C gene, and the 
regulatory sequences of the mouse whey acidic protein promoter in the 5' 4.2 kb Sau3A-
Kpn1 promoter fragment of the mouse whey acidic protein promoter, most particularly 
when they are used together. 
Especially useful in the present invention are sequences that advantageously modulate 
post-translational modifications of protein C, such that the protein C produced in the 
transgenic animals of the invention is active. In particular, the genomic sequences of the 
human protein C gene are preferred. Thus, in accordance with the present invention a 
DNA sequence that encodes protein C is operably linked to cis-acting regulatory 
sequences which allow for efficient expression of protein C in milk. The resulting 
chimeric DNA is introduced into a mammalian embryo, where it integrates into the 
embryonic genome and becomes part of the heritable genetic endowment of all the cells, 
including the germ line cells, of the adult which develops from the embryo. The protein C 
which is expressed in the mammary tissue and secreted into the milk of a transgenic 
mammal obtained in this manner displays a surprisingly high percentage of active 
protein, as measured by enzymatic and coagulation-inhibition assays which are 
conventionally employed to detect protein C activity, such as ELISAs, chromogenic 
activity assays and coagulation inhibition assays. Levels of active protein on the order of 
80% to 90% or more are characteristic of the protein C expressed in accordance with the 
present invention. Obtaining milk from a transgenic animal within the present invention 
is accomplished by conventional means. McBurney et al., J. Lab. Clin. Med. 64: 485 
(1964). The protein C contained in such milk can be purified by known means without 
unduly affecting activity. One suitable approach to purification in this regard is 
immunoaffinity chromatography. Alternatively, the expressed protein C can be isolated 
from the milk by other conventional means, for instance, by the method of Kisiel, J. Clin. 
Invest. 64: 761 (1979). In any event, it is preferred that protein C produced in milk 
pursuant to the present invention should be isolated as soon as possible after the milk is 
obtained from the transgenic mammal, thereby to mitigate any deleterious effect(s) on the 
stability of the protein. 
The present invention is further described by reference to the following, illustrative 
examples. 
EXAMPLE 1 
DNAs Useful for Expressing Protein C in Transgenic Animals 
The entire murine WAP gene including 2.5 kb of 5' untranslated sequence and 3' 
untranslated regions was cloned by standard methods. See Campbell et al., Nucleic Acids 
Res. 12: 8685 (1984). The human placental cDNA for human protein C was obtained 
from C. Shoemacker. Human genomic DNAs encoding protein C were cloned by 
standard methods from a human placental genomic library. The 9.4 kb fragment was 
assembled from two genomic clones and a SalI, MseI ended 60 bp synthetic 
oligonucleotide that was added to the 5' end of the gene. 
Standard recombinant DNA techniques were employed to generate the vectors and 
expression constructs of the preferred embodiments, and for other manipulations of 
DNA, as set forth below. See Sambrook et al., MOLECULAR CLONING, A 
LABORATORY MANUAL, Vol. 1-3 (Cold Spring Harbor Press 1989). 
(1) WAPpC1 
A DNA construct called WAPpC1 was made, consisting of the entire murine WAP gene 
containing one copy of human protein C cDNA inserted at the unique KpnI site, 24 base 
pairs 3' of the transcriptional start site of the WAP gene (FIG. 1). This WAP-protein C 
construct was ligated into a bluescribe vector (Stratagene) to facilitate further 
manipulation. 
(2) WAPpC2 
WAPpC2 is similar to WAPpC1, comprising the entire murine WAP gene and human 
protein C cDNA but differs from WAPpC1 in lacking artefactual 5' flanking sequences 
present in WAPpC1 as a result of cloning procedures used to make that construct. 
Specifically, 33 bp 5' to the protein C ATG and 118 "A's" at the 3' end of the protein C 
cDNA were removed by PCR, and new KpnI sites were added at the 5' and 3' ends. 
EXAMPLE 2 
Preparation of DNAs for Microinjection 
DNA for microinjection was prepared according to the procedures described below for 
DNA from WAPpC1. 
The 9 kb WAPpC1 fragment was removed from the vector with the restriction enzyme 
EcoRI. After digestion with EcoRI the solution containing the WAPpC1 DNA was 
brought to 10 mM magnesium, 20 mM EDTA and 0.1% SDS and then extracted with 
phenol/chloroform. DNA was precipitated from the aqueous layer with 2.5 volumes of 
ethanol in the presence of 0.3 M sodium acetate at -20.degree. C. overnight. After 
centrifugation, the pellet was washed with 70% ethanol, dried, and resuspended in sterile 
distilled water. 
DNA for microinjection was purified by HPLC. The digested DNA was precipitated with 
isopropanol and then dissolved in TE buffer at 0.3 .mu.g/ml. Fragments were purified by 
HPLC using a Waters GEN FAX PAC HPLC column. The column was run isocratically 
using a buffer consisting of 25 mM Tris-HCl (pH 7.5), 1 mM sodium EDTA, and 0.63 M 
NaCl. This is the minimum NaCl concentration that will elute the large construct 
fragment and results in the best resolution from the smaller vector fragment which elutes 
just prior to the construct fragment. About 15 .mu.g of digested DNA was loaded on the 
column at a time. The construct-fragment samples from all of the chromatographic runs 
were then pooled, reprecipitated, and run through the column a second time. Results 
reported below, for both pigs and mice, were generated using HPLC-purified DNA. 
DNA concentrations were determined by agarose gel electrophoresis by staining with 
ethidium bromide and comparing the fluorescent intensity of an aliquot of the DNA with 
the intensity of standards. Samples were then adjusted to 10 .mu.g/ml and stored at -
20.degree. C., prior to microinjection. 
EXAMPLE 3 
Transgenic Animals 
(1) Mice 
Transgenic mice were produced essentially as described by Hogan et al., 
MANIPULATING THE MOUSE EMBRYO (Cold Spring Harbor Press 1986). The 
procedures employed are outlined below. 
Glass needles for micro-injection were prepared using a micropipet puller and 
microforge. Injections were performed using a Nikon microscope having Hoffman 
Modulation Contrast optics, with Narashigi micromanipulators and a pico-injector driven 
by N.sub.2 (Narashigi). Fertilized mouse embryos were surgically removed from the 
oviducts of superovulated female CD-1 mice and placed into M2 medium. Cumulus cells 
were removed from the embryos with hyaluronidase at 300 .mu.g/ml. The embryos were 
then rinsed in new M2 medium, and transferred into M16 medium for storage at 
37.degree. C. prior to injection. 
After injecting the DNA solution into the male pronucleus, embryos were implanted into 
avertin-anesthetized CD-1 recipient females made pseudo-pregnant by mating with 
vasectomized males. Embryos were allowed to come to term and the newborn mice were 
analyzed for the presence of the transgene as described below. 
(2) Pigs 
Embryos were recovered from the oviduct. They were placed into a 1.5 ml microfuge 
tube containing approximately 0.5 ml embryo transfer media (phosphate buffered saline 
+10% fetal calf serum, Gibco BRL). These were then centrifuged for 12 minutes at 
16,000.times.g RCF (13,450 RPM) in a microcentrifuge (Allied Instruments, model 
235C). Embryos were removed from the microfuge tube with a drawn and polished 
Pasteur pipette and placed into a 35 mm petri dish for examination. If the cytoplasm was 
still opaque with lipid such that pronuclei are not visible, the embryos were centrifuged 
again for 15 minutes. Embryos to be microinjected were placed into a microdrop of 
media (approximately 100 .mu.l) in the center of the lid of a 100 mm petri dish. Silicone 
oil was used to cover the microdrop and fill the lid to prevent media from evaporating. 
The petri dish lid containing the embryos was set onto an inverted microscope (Carl 
Zeiss) equipped with both a heated stage and Hoffmnan Modulation Contrast optics 
(200.times.final magnification). A finely drawn (Kopf Vertical Pipette Puller, model 720) 
and polished (Narishige microforge, model MF-35) micropipette was used to stabilize the 
embryos while about 1-2 picoliters of HPLC-purified DNA solution containing 
approximately 200-500 copies of DNA construct was delivered into the male pronucleus 
with another finely drawn micropipette. Embryos surviving the microinjection process as 
judged by morphological observation were loaded into a polypropylene tube (2 mm ID) 
for transfer into the recipient pig. 
(3) Other Animals 
Methods for microinjection of other animal species are similar to the methods set forth 
above. 
EXAMPLE 4 
Assessment via PCR of WAP/hPC Constructs in Transgenic Animals 
(1) Preparation of DNA Form Transgenic Animals 
DNA can be prepared from tissue of a transgenic animal of any species by the method 
exemplified below for mice. 
A 5 mm piece of mouse tail was removed from young, potentially transgenic mice at 
weaning (3 weeks of age), minced, and treated with proteinase K and SDS at 37.degree. 
C. overnight. The mixture was then incubated with DNase-free RNase at 37.degree. C. 
for 1-2 hours. DNA was precipitated from the mixture with sodium acetate and ethanol at 
-20.degree. C. overnight, collected by centrifugation, washed in 70% ethanol and dried. 
The dried DNA pellet was used directly for PCR. In some cases the mixture was 
extracted extensively with phenol/chloroform prior to ethanol precipitation. 
Essentially the same technique was used to prepare DNA from pigs, and the same or 
similar techniques can be used to prepare DNA from other animals. 
(2) Oligonucleotide Probes Used in the PCR Assay 
Oligonucleotide pairs were used to prime polymerase chain reactions that detected the 
presence of WAP-protein C constructs in the transgenic animals. These pairs and their 
extension products are shown schematically in FIG. 2. Oligonucleotide pairs that bridge 
the region from the WAP sequences 5' of the KpnI site and the endogenous WAP 
sequences which naturally lie 3' of the KpnI site also provided positive controls in mice. 
(3) PCR Reaction Conditions and Product Analysis 
PCR reactions were performed using an annealing temperature of 58.degree. C., a 
denaturation temperature of 94.degree. C., and an extension temperature of 72.degree. C., 
using 100 ng of oligo primers and 50 ng of (genomic) template DNA per reaction, and 
cycling through the temperatures 40 times using an automatic temperature cycler (M.J. 
Research). 
PCR reactions were analyzed by running 20% of the reaction products on agarose gels 
and identifying fragment sizes by comparison with marker DNA fragments. 
(4) Results of PCR Analysis of Transgenic Animals 
PCR analysis of potentially transgenic mice and pigs which developed from embryos 
microinjected with WAPpC1 and WAPpC2 constructs are summarized in Table 2. The 
results show that WAPpC constructs frequently integrated into the embryonic genomes of 
both mice and pigs. Furthermore, mendelian transmission was observed in 5 of the 16 
mice which were tested. 
                             TABLE 2
     Whey Acid Protein-Protein C Construct Integration Rates
        Animal     # Tested     # Positive    Integration Rate
        Mice          105          30              29%
        Pigs           23           5              22%
    Mendelian Transmission in Transgenic Mice 5/16 Tested = 31%
EXAMPLE 5 
Preparation of Milk and Whey from Transgenic Animals 
Lactating mice were milked an average of 3 times per week. The mice were first 
separated from their young for approximately 5 hours. They were then anesthetized with 
0.4 ml avertin at 2.5% (I.M.), and 0.2 ml oxytocin was then administered at 2.5 IU/ml 
(I.P.) to permit release of the milk. A milking device consisting of a vacuum pump (2.5 
psi) and syringe with an eppendorf tip was used to direct milk into an eppendorf tube. 
During collection, milk was placed on ice until all samples were obtained. 
To prepare whey, milk was diluted 1:1 with TS buffer (0.03 M Tris pH 7.4; 0.06 NaCl) 
and centrifuged in a TLA-100 rotor in a Beckman TL-100 table top ultracentrifuge at 
51,000 rpm (89,000.times.g) for 30 minutes at 4.degree. C. After centrifugation the tubes 
were put on ice, and the whey was collected with an 18 gauge needle, leaving the casein 
pellet and upper cream layer in the tube. To remove solids or cream that co-transferred 
during the initial recovery, the whey obtained from the first centrifugation was subjected 
to a second spin at 12,000 rpm for 30 minutes at 4.degree. C. in a TMA-4 rotor in a Tomy 
MTX-150 centrifuge. Following the second spin the tubes were place on ice and the 
whey was recovered as before. 
EXAMPLE 6 
Determination by ELISA of Protein C Produced by Transgenic Mammals 
An ELISA was used to measure the amount of protein C protein produced by transgenic 
animals in their milk or whey. Two monoclonal antibodies, 7D7B10 and 12A8, and a 
polyclonal antiserum were used in the ELISAs, and a variety of other protein C specific 
antibodies could be employed. The 7D7B10 monoclonal is specific for the NH.sub.2 
terminus of the light chain of protein C. 12A8 is specific for the reactive site on the heavy 
chain of protein C. Microtiter plate wells were coated overnight at 4.degree. C. with 3 
.mu.g/ml of monoclonal antibody in 50 .mu.l of 0.1 M sodium bicarbonate buffer, pH 8.3. 
The wells were washed once with TET buffer (0.01 M Tris pH 7.5; 0.01 M EDTA; 
0.02% tween-20, pH 7.45) and then blocked with 1% BSA in PBS using 400 .mu.l per 
well for 1 hour at 37.degree. C. Plates were again washed with TET buffer (5.times.) 
followed by addition of 100 .mu.l of sample whey or normal whey spiked with human 
protein C from plasma, to generate a standard curve. After washing 5.times. with TET 
buffer, horse radish peroxidase (HRP)-conjugated to rabbit anti-hPC was diluted 1:1000 
in 0.1% BSA/TET and 100 .mu.l was added per well and incubated for 2 hours at room 
temperature, with shaking at 100 rpm. After again washing 5 times with TET buffer, 100 
.mu.l of orthophenyldiamine (OPD), from a stock solution made by dissolving one tablet 
of OPD in 20 ml of 0.1 M citrate-phosphate buffer (pH 5.0), were added to each well. 
After 10 minutes at room temperature the reaction was stopped with 1 N sulfuric acid. 
The extent of the reaction was determined by measuring product absorption at 490 nm. 
The result of an ELISA analysis of the milk from one transgenic mouse (Mouse No. 5) is 
shown in FIG. 3. Standard curves were obtained for a monoclonal antibody, 12AB, and a 
rabbit polyclonal antibody, tittered against human protein C which was obtained by 
immunoaffinity chromatography over immobilized 7D7B10 antibody. The milk sample, 
taken from transgenic Mouse No. 5, contained approximately 200 ng/ml protein C. 
To assure proper protein C structure as judged by immunocapture by two different 
monoclonal antibodies, as well as by a polyclonal mixture of antibodies, the samples for 
several different transgenic mice were screened by ELISAs. Table 2A shows essentially 
equivalent antigen levels, as judged by three different immunocaptures and detection by 
ELISA. The majority of mice produced by microinjection of WAPpC1 produced antigen 
levels in the 1-to-4-.mu.g/ml range. 
                     TABLE 2A
                    hPC ANTIGEN ELISA (NG/ML)
    MOUSE        MONOCLONAL       MONOCLONAL       POLYCLONAL
    ID-DAY       LC-CAPTURE       HC-CAPTURE         CAPTURE
    Y52-15          1820             3530             4100
    Y57-15           930             1150             2880
The concentration of human protein C in whey obtained from transgenic mice, as well as 
milk, was also determined in this manner, with equivalent results. 
Similar assays were routinely carried out to assay protein C in milk obtained from 
transgenic animals. Results obtained using the 7D7B10 antibody in light-chain capture 
ELISAs are compiled in Table 3, which summarizes the concentration of protein C in 
milk obtained from transgenic mice during the first four lactation periods. Dashes 
indicate that no test was done. All of the animals provided significant levels of protein C 
in their milk. Preliminary results also indicate that the second lactation period is 
sometimes superior to the other periods tested. 
                             TABLE 3
            hPC ELISA SCREENING (LIGHT CHAIN CAPTURE)
                                PC-Ag (.mu.g/ml)
                                Day of Lactation
        MOUSE ID       5-6       8-9       11-12       13-15
        Y68-L2         --       1.05        -- --
        Y51-L2         --       1.08        --         0.56
        Y51-L3         --       2.80       1.30        1.79
        Y52-L1         --       0.55       0.65         --
        Y52-L2         --       1.52        --         0.95
        Y57-L1         -- --        0.52        1.35
        Y57-L2        1.47       --        0.98         --
        R03-L2        1.90      2.88       3.01         --
        R12-L1         --   0.60        -- --
        R12-L2         --       2.98       2.48        2.40
Human protein C in the milk obtained from other species can be measured by the same 
methods. Thus, protein C from human plasma spiked into pig milk was accurately 
detected via the above-described ELISA. 
EXAMPLE 7 
Assay for Protein C Amidolytic Activity Using the Chromogenic Substrate S-2366 
(1) Microtiter Well Assay 
The enzymatic activity of protein C in the milk of transgenic animals was measured 
directly using a chromogenic assay essentially as described by Odegaard et al., 
Haemostasis 17: 109 (1989). In this assay microtiter plate wells were coated with the 
7D7B10 monoclonal antibody (50 .mu.g/ml) in 50 .mu.l of 0.1 M bicarbonate buffer, pH 
8.6 at 4.degree. C. overnight. Plates were then rinsed with TET buffer (0.1 M Tris; 0.03 
M EDTA; 0.05% tween-20) and blocked with 400 .mu.l/well 1% BSA in PBS and 
incubated at room temperature for 1 to 1.5 hours. After rinsing 3 times with TET buffer, 
50 .mu.l of whey sample and 50 .mu.l of 0.1 M Tris pH 7.5, 0.03 M EDTA was added per 
well and incubated at room temperature for 2 hours. Plates were washed 3 times in TET 
buffer. The captured human protein C was activated by adding 120 .mu.l of Protac.TM., a 
commercial reagent containing a snake-venom enzyme (12 ml distilled water per vial), 30 
.mu.l TSP buffer and 0.1% BSA, pH 7.5, per well. After incubation for 6-10 minutes at 
room temperature, 120 .mu.l S-2366 (Kabi substrate) at 25 mg/10.8 ml Tris pH 7.8 was 
added to each well and the plates were incubated for 2-8 hours at room temperature, or 
several days at 4.degree. C. The amount of protein C activity in each sample was 
determined by measuring formation of the reaction product by absorption at 405 mm. 
Results obtained using milk and whey from a transgenic mouse and the pooled milk and 
whey of several transgenic mice appear in Table 4, which shows the amount and the 
specific activity of protein C in the samples. Note that the samples were obtained either 
during the first lactation period, L1, or were obtained from a second and third lactation, 
L2 and L3. The specific activity of the human protein C obtained from transgenic mice 
determined in these assays, 205 units (U) per mg, is similar to that of human protein C of 
similar purity obtained from natural sources. (A "unit" is defmed by pooling blood from 
many individuals and determining activity in 1 ml of the pooled blood.) 
                             TABLE 4
      Protac .TM. -Specific Amidolytic Activity Upon S-2366
                             U/ml     .mu.g Ag/ml     U/mg
        Reconstituted Whey      0.07       0.34         206
        Y52-L1 Pool*
        Y52-L1 Milk Pool*       0.23       1.12
        Transgenic Whey Pool**    1.12       0.55         205
  Transgenic Milk Pool**    0.43       2.10
    *Pooled milk from day 5-15.
    **L2 and L3 from mice Y51, Y52, Y57, R03, R12.
(2) Amidolytic Activity Assay on Nitrocellulose 
Whey proteins were resolved by electrophoresis through polyacrylamide gels under non-
reducing conditions in the presence of SDS. Following electrophoresis proteins were 
transferred out of the gel and immobilized on a nitrocellulose membrane by 
electroblotting. SDS was removed from the membrane by thorough washing in 0.05 M 
Tris-Cl, 0.175 M NaCl, 0.25% Triton X-100, pH 8.0, and the membrane was then 
equilibrated in 0.25 M Tris-Cl pH 8.0. Following equilibration the membrane was 
incubated in Protac C, 0.25 U/ml in distilled water. A 1% agarose indicator gel in 25 mM 
Tris-Cl pH 8 containing 1 mM chromogenic substrate S-2366 was then placed onto the 
gel, and the filter and gel overlay were incubated under moist conditions for 30-90 
minutes at 37.degree. C. Colored bands generated by protein C activity on the filter were 
visualized under U.V. light, and photographed. 
FIG. 8 shows the results obtained by this assay for milk produced by transgenic mice that 
were stably transformed with a double stranded DNA comprising the 5' 4.2 kb WAP 
promoter ligated via a linker to the 9.4 kb human genomic protein C fragment. All of 
these transgenic mice produced amidolytically active protein C in their milk, giving rise 
in the blots to a strong band and a weak band of amidolytic activity (FIG. 8, panel A). 
Notably, bands of the same migration were detected in each whey sample when a similar 
blot was probed with an anti-protein C antibody (FIG. 8, panel B). 
EXAMPLE 8 
Determination of Protein C Produced in Transgenic Mammals by Activated Partial 
Thromboplastin Clotting Time Assay 
The activity of protein C was also measured in a clotting time assay, the activated partial 
thromboplastin clotting time assay (APTT). In this assay, each well of a plastic Coag-a-
mate tray received 90 .mu.l of PC-deficient plasma plus 10 .mu.l of an APC standard or 
unknown, diluted with Tris/saline/BSA. The tray was then placed on an automated 
analyzer (APTT mode, 240 second activation). The run was started, which automatically 
performed the addition of 100 .mu.l of APTT reagent and 100 .mu.l of 0.025 M 
CaCl.sub.2. Data obtained using a standard APC preparation was fitted to the equation y-
ax+b where y=clotting time and x=APC, which was then used to determine the amount of 
APC in a sample. 
The result of an APTT assay of whey pooled from transgenic mice is shown in FIG. 4. 
The standard curves in the figure correlate the activity determined by the APTT assay 
with the amount of active human protein C in mouse milk or mouse whey. The activity in 
the APTT assay of the whey sample obtained from the transgenic mouse corresponded to 
a concentration of approximately 0.57 .mu.g/ml, interpolated from the standard curve for 
human protein C in whey. An ELISA (not shown) of the same whey sample detected 
approximately 0.60 .mu.g/ml of human protein C, as protein. Thus, within the normal 
range of error of these assays, human protein C produced in transgenic mice is as active 
as the control human protein C. 
EXAMPLE 9 
Mapping of Calcium Dependent Conformer by Metal-Dependent Immunoaffinity 
Standard ELISAs were run in normal mouse milk whey with varying concentrations of 
hPC or hPC without Gla regions in the presence of 25 mM EDTA. After capture by 
7D7B10, an assay replicating that effected with 25 mM EDTA was treated with several 
washes of 25 mM CaCl.sub.2, and then was followed by the ELISA detection protocol 
described previously. While de-Gla protein remained bound to the capture antibody in the 
presence of CaCl.sub.2, the PC standard did not remain bound in the presence of added 
CaCl.sub.2. It was observed that whey from the transgenic mouse Y57 behaved in a 
similar manner to the .gamma.-carboxylated native PC, suggesting that it is also 
.gamma.-carboxylated like the native molecule. 
EXAMPLE 10 
Purification of Human Protein C from the Milk of Transgenic Animals 
(1) Preparation of Whey Samples 
Milk from several WAPpC1 transgenic mouse lines was pooled, chilled on ice, diluted 6-
fold with 50 mM Tris-HCl, 0.15 M NaCl pH 7.2 (TBS) (1 ml milk per 5 ml TBS), and 
centrifuged at 125,000.times.g for 30 minutes at 4.degree. C. Following centrifugation, 
the whey was collected and pooled using a pasteur pipet and pooled, being careful not to 
disturb the fatty overlayer or the casein pellet. Samples were removed from the pool for 
later assay and then both the samples and the pooled whey were frozen and stored at -
90.degree. C. Human protein C in samples was determined by ELISA, as described 
above. 
Individual whey pools were thawed at 2.degree. C.C, combined, and the amount of 
human protein C (hPC) in the combined pool was determined by ELISA using the 
7D7B10 monoclonal antibody (Mab). The combined pool contained approximately 30 
.mu.g hPC, determined by this assay, which was within 20% of the total determined by 
adding determinations of the individual pools. 
The combined pool, approximately 150 ml, was dialyzed (14,000 MW cutoff) against 25 
mM EDTA-TBS diluted 5-fold with pure water. The dialyzed whey was concentrated 5-
fold by lyophilization and subsequent reconstitution with nanopure water, to yield a final 
buffer concentration equivalent to 25 mM EDTA in TBS, and a 5-fold increase in protein 
concentration. The concentrated whey contained 930 mg protein, as estimated by optical 
absorption at 280 nm, at 16 mg/ml. 
2) Immunoaffinity Chromatography 
The resin immunosorbent (Affiprep.TM.) used to purify human protein C in the whey of 
transgenic mice contained 3.3 mg 7D7B10 Mab/ml of Affiprep resin. The 7d7B10 
Affiprep resin was assessed by mock immunopurification using 30 .mu.g of plasma 
derived hPC doped into control (nontransgenic) mouse whey. Approximately the same 
relative amount of total protein was loaded onto the column (660 mg on a 10 mL 
Affiprep) and otherwise processed as described below. 
Freshly concentrated whey (16 mg/ml, 930 mg total protein, as determined by optical 
absorption at 280 nm) was batch-loaded onto 13 ml of 7D7B10 Affiprep containing 3.3 
mg 7D7B10 Mab/ml resin for 4 hours at 2.degree. C., without addition of carrier protein. 
The column was fresh and the high total (background) protein loading was thought to be 
enough to condition the column. The resin was then loaded into a 1 cm diameter column 
and washed with 25 mM EDTA-TBS until baseline optical density (O.D.) was detected at 
280 nm (3 column volumes to obtain <0.0005 O.D.) 
The column was then eluted with 25 mM CaCl.sub.2 in TBS pH 7.2, followed by 100 
mM CaCl.sub.2 in TBS, followed by 4 M NaCl, followed by 2 M Na thiocyanate at 0.5 
ml/min. The column was re-equilibrated with 5 column volumes of 25 mM EDTA-TBS, 
0.02% sodium azide. 
All peak pools were dialyzed in a 100-fold dilution (by nanopure water) of 50 mM 
imidazole, 0.1 M NaCl buffer using a 14,000 MW cutoff dialysis tubing, then 
lyophilized, then reconstituted to 50 mM imidazole, 0.1 NaCl buffer strength using 
nanopure water resulting in a 100-fold concentration of protein. 
Samples of these eluate pool concentrates were prepared as per the method of Laemmli 
(1970), applied to a 15 well, 9 cm.times.2 cm, 4% stacking gel above a 7.5 cm, 7.5% 
resolving (30%: 2.7% bis) sodium dodecylsulphate polyacrylamide gel and 
electrophoresed (SDS-PAGE). After electrophoresis, the gel was stained with 1.25% 
Coomassie Blue dye solution. 
The area of the eluate peaks obtained from immunopurification of whey from WAPpC1-
transgenic mice was found to be very similar to the mock trial using an equivalent 
amount of (plasma derived) hPC-doped whey from control mice. Assay of 100-fold 
concentrated 25 mM CaCl.sub.2 eluate product from WAPpC1 transgenics showed 40% 
yield based upon densitometry of SDS-PAGE stained with Coomassie Blue (yield not 
determined for mock purification). The total peak areas from mock- and WAPpC1-whey 
were approximately the same for all eluate peaks including the 2 M Na thiocyanate peak. 
Approximately 2 .mu.g of hPC antigen (ELISA with immunocapture using 7D7B10 
Mab) was detected in the column fallthrough which had been combined with EDTA-TBS 
wash. Approximately 14 .mu.g of hPC was detected in the 25 mM Ca.sup.2+ eluate pool, 
less than 0.1 .mu.g hPC antigen in the 100 mM Ca.sup.2+ eluate pool, no hPC antigen 
was detected in the 4 M NaCl pool, approximately 10 .mu.g of hPC was detected in the 2 
M Na thiocynate eluate pool. Thus, 87% of the hPC antigen applied to the column was 
accounted for in the total antigen recovered from column effluents. A 47% antigen yield 
was obtained based upon the hPC antigen recovered in the 25 mM Ca.sup.2+ eluate peak. 
The starting whey applied to the column, the 2 M sodium thiocyanate eluate, the 25 mM 
Ca.sup.2+ eluate product, and a reference hPC derived from plasma by the American Red 
Cross (Lot #28300277, supplied by Dr. Carolyn Orthner) were analyzed by SDS-PAGE, 
both reduced and non-reduced. The 2 M sodium thiocynate and 25 mM Ca.sup.2+ eluate 
pools were concentrated as described above and 4 .mu.g of antigen applied to the gel for 
each lane. The immunopurified hPC reference was applied to the gel as 4 .mu.g total 
protein based upon O.D. at 280 nm. Scanning densitometry of this reference hPC 
indicated that the sample was greater than 99% pure on nonreduced SDS-PAGE, and 
71% pure on reduced SDS-PAGE. Subsequent antigen assays performed on the hPC 
reference material indicated the concentration of the sample to be such that only 2.7 
.mu.g of the reference sample was applied to the gel. The 25 mM Ca.sup.2+ eluate 
product is greater than 94% pure based upon non-reduced SDS-PAGE and 86% pure 
based upon reduced SDS-PAGE. The staining intensity of the 25 mM Ca.sup.2+ eluate 
lanes is consistent with our previous experience for 4 .mu.g antigen applications. The 
bands corresponding to reference hPC possessed lighter intensity relative to the 25 mM 
Ca.sup.2+ eluate. A slightly split band at approximately 62,000 relative molecular weight 
(Mr) is seen for both the non-reduced reference hPC and the 25 mM Ca.sup.2+ eluate. A 
doublet at about 40,000 Mr and a diffuse single band at 22,000 Mr is seen for both the 
reduced reference hPC and 25 mM Ca.sup.2+ eluate. The 22,000 Mr band appearing in 
the hPC reference is seen to be somewhat more diffuse or heterogeneous than the similar 
band appearing in the 25 mM Ca.sup.2+ eluate from the whey of transgenic mice. The 
sodium thiocyanate peak showed a band in excess of 180,000 Mr in the nonreduced 
sample and multiple bands at 50,000 Mr and 25,000 Mr in the reduced sample. 
The chromatography of the WAPpC1-whey was nearly identical to the mock run using 
plasma-derived hPC doped into control whey. The total areas and yields of hPC in the 25 
mM Ca.sup.2+ eluates and areas of 2 M sodium thiocyanate peaks for both runs were 
similar and thus the binding characteristics of the 7D7B10 Mab onto transgenic hPC or 
plasma-derived hPC were similar. This is consistent with the similarity found between 
plasma-derived and transgenic hPC Ca.sup.2+ - dependent conformers as judged by 
ELISA assays using the 7D7B10 Mab to immunocapture from whey. The primary 
structure as judged by SDS-PAGE appears to be similar, with the amount of .alpha.-form 
and .beta.-form heavy chain being essentially the same for plasma-derived and transgenic 
hPC; the transgenic having 68% .alpha.-form and 32% .beta.-form while the plasma-
derived material possessed 69% .alpha.-form and 31% .beta.-form. The light chains were 
also similar in size for both reference and transgenic hPC. Previous experience with SDS-
PAGE using Coomassie Blue staining of hPC has shown linearity for both chains over 
the range of 2-5 .mu.g hPC applied to the gel. Thus, much of the elements of post-
translational, proteolytic processing appears to have occurred properly in the mammary 
tissue. 
The purity of these runs also demonstrates the satisfactory utility of the 
immunopurification procedure developed for the murine system. It is believed that the 
tight binding of the hPC antigen found by ELISA in the 2 M thiocyanate peak of the 
whey from transgenic mice (assay not done for mock run) is typical of yields found for 
fresh immunosorbents and not due to an aberrant hPC structure. The total background 
protein did not seem to condition the column and thus the interaction is thought to be 
specific with the 7D7B 10 Mab. Overall, this two step procedure results in a minimum 
purification factor of 27,000 for the hPC recovered from mouse milk. A large-scale 
purification process could employ a citrate or EDTA precipitation coupled with low 
speed centrifugation in place of the ultracentrifugation step used for mouse milk. 
Both amidolytic and anti-coagulant assays were performed upon immunopurified milk 
from transgenic mice. Within the sensitivity of these assays, the amidolytic and anti-
coagulant activity was the same as plasma-derived immunopurified protein C. For both 
types of assays, the specific activity was greater than 270 U/mg. 
EXAMPLE 11 
Highly Efficient Expression of Active Protein C in Transgenic Mammals Using a Long 
Mouse Whey Acid Protein Promoter Fragment and a Human Genomic Protein C 
Fragment 
(A) DNA Constructs 
The 5' 4.2 kb Sau3A-Kpn1 promoter fragment of the mouse whey acidic protein 
promoter was cloned by standard techniques. This Sau3A-KpnI WAP promoter is 4122 
basepairs in length and has the GenBank Accession No. X79437. The nucleotide 
sequence of the Sau3A-KpnI WAP promoter (SEQ ID NO: 1) is shown in FIG. 9. The 
9.4 kb genomic fragment of human protein C beginning 21 basepairs upstream of the "A" 
in the protein C start codon and ending at the NheI site in the 3' end of the protein C gene 
also was cloned by standard techniques. The 4.2 kb promoter fragment and the 9.4 kb 
protein C fragment were joined using a SalI linker, as shown in FIG. 6. 
(B) Production of Transgenic Animals 
DNA was prepared and injected into mouse and pig embryos as described hereinabove. 
Animals were tested for integration of the DNA by PCR, also as described above. Stable 
integration of the construct was detected in both mice and pigs. 
(C) Protein C in the Milk of Transgenic Mice 
The mice were reared to maturity, crossed and milk was obtained from lactating females. 
FIG. 7 depicts SDS-PAGE and western blot analysis of whey from six transgenic mice. 
As shown in panel A, transgenic mouse whey (lanes 1-6) and normal mouse whey (lane 
7) gave rise to substantially the same silver stain pattern of bands after SDS-PAGE. As 
shown panel B, human protein C readily was detected in the transgenic mice whey (lanes 
1-6), but not in normal mouse whey (7), when the samples were blotted onto 
nitrocellulose, probed with an anti-human protein C antibody, and visualized by 
chemiluminescence. The pattern of bands detected by the anti-human protein C antibody 
in the transgenic mouse whey was very similar to the pattern of bands detected in purified 
human protein C (lane 8). 
As shown in FIG. 8, protein C activity readily could be detected in transgenic mouse 
whey. Panel B in the figure shows the pattern of human protein C in mouse whey 
samples resolved by SDS-PAGE under non-reducing conditions. Protein C was 
visualized by blotting onto nitrocellulose, probing the filter with an anti-human protein C 
antibody and detecting antibody binding by a secondary-antibody- enzyme conjugate and 
the chromogenic substrate 4-chloro-1-naphthol. Protein C reactive bands were 
substantially the same in transgenic mice (lanes 3-8) and purified human protein C (lane 
1), and were absent from normal mouse whey (lane 2). 
Amidolytic activity in the samples is shown in Panel A. An agarose gel overlay 
containing chromogenic substrate revealed enzyme activity in whey from each transgenic 
mouse (lanes 3-8) and in purified human protein C (lane 1), but not in normal mouse 
whey (lane 2). The amounts of human protein C produced by the transgenic mice in their 
milk also was determined. Table 5 shows the amounts of human protein C detected in the 
milk of six transgenic mice, as determined by 12A8 monoclonal ELISA and by sheep 
anti-human protein C polyclonal ELISA. The table also shows protein C amidolytic 
activity in whey from the same samples. The ELISAs and the amidolytic activity assay 
were performed as described hereinabove. 
As shown in the Table 5, protein C concentrations in the transgenic mice by monoclonal 
ELISA ranged from approximately 0.05 mg/ml to approximately 1.69 mg/ml. The 
concentration of protein C in the milk of these mice was at least 40 fold more than the 
concentration of protein C observed in other transgenic mice, such as those noted in 
Table 2A, as set forth hereinabove. 
Concentrations measured by polyclonal ELISA ranged from 0.14 to 4 mg/ml, exceeding 
even more dramatically the concentrations attained with the 2.4 kb 5' WAP promoter, the 
highest of which, as set forth in Table 2A, was 0.0041 mg/ml. 
In addition, whey samples from the transgenic mice were assayed for amidolytic activity 
and the results were compared with amidolytic activity of protein C in plasma. 
Amidolytic activity in the samples is shown in Table 5, expressed as the per cent of 
protein C activity in plasma. The concentration of protein C in the whey samples was 
adjusted to equal the concentration in the normal plasma control. 
The high concentration of protein C allowed the amidolytic activity to be assayed directly 
in whey. This contrasted sharply with the necessity to use a capture method to 
concentrate protein C prior to amidolytic activity of whey samples from mice transgenic 
for the 2.4 kb WAP promoter fragment. 
The amidolytic activity of protein C in the whey sample was also compared with the 
activity of purified human protein C diluted in whey. At comparable concentrations of 
protein C, amidolytic activity in transgenic mouse whey was nearly the same as that of 
human protein C. 
                             TABLE 5
    Detection of human protein C in the milk of transgenic mice having
    the 5' 4.2 kb WAP-promoter-9.4 kb human genomic protein C
           construct stably integrated in their genomes
                                       PC ANTIGEN
               TRANS-    PC ANTIGEN     BY POLY-     AMIDOLYTIC
    MOUSE       GENE      BY 12A8-       CLONAL      ACTIVITY IN
    NUM-        COPY      MAB ELISA       ELISA      WHEY (% N-
    BER        NUMBER      (mg/ml)       (mg/ml)       PLASMA)
    5.4          14     0.05 .+-. -0.01 0.14 .+-. -0.01     N.D.
    6.4          10     1.00 .+-. -0.03 2.94 .+-. -0.09     56.2
    4.2.10       10     1.69 .+-. -0.09 3.98 .+-. -0.09     54.8
    5.2.12       20     0.96 .+-. -0.09 2.50 .+-. -0.10     54.9
    7.2.2         2     0.33 .+-. -0.03 0.89 .+-. -0.14     N.D.
    7.5.4        30     0.96 .+-. -0.04 1.99 .+-. -0.33     18.8
Finally, some of the transgenic mice were sacrificed and examined to determine the tissue 
specificity of expression of human protein C. RNA blots and immuno in situ histological 
examination showed that at least 99% of the protein C expression occurred in the 
mammary glands in these animals. These results contrast with the results achieved using 
whey acidic protein promoter constructs that contained only the 2.4 kb promoter 
fragment. Constructs using this promoter to drive protein expression in transgenic mice 
engendered expression that differed from the normal pattern of whey acidic protein 
expression during development and in adult tissues. In fact, this was true for the whey 
acidic protein itself. Thus, in addition to providing high levels of expression of a protein, 
the 4.2 kb 5' WAP promoter fragment also provides greater tissue specificity of 
expression in the adult mouse. 
(D) Purification of Protein C from Transgenic Mouse Whey 
Human protein C was partially purified from transgenic mouse whey by immunoaffmity 
chromatography using the 12A8 monoclonal antibody immobilized on a Sepharose 
support. Bound protein C was eluted in 0.1 M glycine, 0.02 M histidine, 0.15 M NaCl pH 
10. Transgenic protein C purified in this manner revealed essentially the same banding 
pattern upon SDS-PAGE as a standard preparation of purified human protein C. 
EXAMPLE 12 
Preparation of DNA Constructs Containing a Mouse Long Whey Acid Protein Promoter 
Fragment and a Factor IX DNA for Expression in Transgenic Animals 
Generally, the entire murine WAP gene was cloned by standard methods, as described 
above. Generally, the entire murine WAP gene including 2.5 kb of 5' untranslated 
sequence and 3' untranslated regions was cloned by standard methods. See Campbell et 
al., Nucleic Acids Res. 12:8685 (1984). A cDNA fragment encoding human Factor IX 
was obtained and the 3' untranslated region was deleted. Using standard methods, an 
expression vector was constructed that contained a mouse WAP promoter, isolated as a 
2.6 kb EcoRI-KpnI fragment immediately 5' to the WAP signal sequence, the human 
Factor IX cDNA sequence lacking a 3' untranslated region, and a 1.6 kb fragment of the 
3' untranslated region of the WAP gene. A second expression vector contained a 7.2 kb 
mouse WAP gene (EcoRI-EcoRI) fragment. Expression vectors were amplified by 
bacterial transformation and purified from bacterial cultures using standard methods. 
Routine recombinant DNA techniques can be found, for example, in Sambrook et al., 
MOLECULAR CLONING, A LABORATORY MANUAL, Vol. 1-3 (Cold Spring 
Harbor Press 1989). More specifically, a chimeric Factor IX construct was prepared, as 
follows: 
(A) Preparation of a Chimeric Factor IX Construct 
1. Production of pWAP4 "Cassette Vector" 
Regulatory 5' and 3' flanking sequences of the mouse WAP gene were used for mammary 
specific expression. Specifically, a cassette vector containing a mouse WAP promoter, 
defined as a 2.6. kb EcoRI-KpnI fragment immediately 5' to the WAP signal sequence 
and a 1.5 kb fragment of the 3' untranslated region of the WAP gene was prepared. These 
regulatory sequences do not include coding and intragenic untranslated sequences 
(introns) of the WAP gene. 
The vector designated pWAP4 was derived from pWAPPC3 (C. Russell, dissertation 
"Improvement of Expression of Recombinant Human Protein C in the Milk of Transgenic 
Mammal Using a Novel Transgenic Construct," Virginia Technology Institute, 
Blacksburg, Va. (December 1993)) and was developed as follows: Using WAPPC3 as a 
template, PCR primers WAP3'S2 (which contains a 5'KpnI site and is homologous to 
endogenous WAP right after the stop signal) and WAP3'A1, as shown in Table 6, below, 
were used to produce a segment with KpnIl and BamHI sites on either end. This segment 
was digested with KpnI/BamHI and ligated with the vector containing the fragment from 
KpnI/BamHI digested pWAPPC3. The ligation mixture was used to transform E. Coli 
DH5.alpha. cells by electroporation with resultant colonies grown on LB ampicillin 
plates. Picked colonies were grown up in TB ampicillin broth, plasmids isolated and cut 
with KpnI, BamHI or both and subjected to gel electrophoresis. Sequencing was 
performed using WAP3'A1 primer and judged as being correct. See FIG. 10A. 
        TABLE 6
        Primer Sequences
     SEQ ID NO: 2
        humFIX5'KpnI         
5'gcta.backslash.ggtacc.backslash.atgcagcgcg
        SEQ ID NO: 3
        humFIX3'KpnI         
5'gtca.backslash.ggtacc.backslash.ttaagtgagct
        SEQ ID NO: 4
        FIXS1                5'ggataacatcactcaaagcac
        SEQ ID NO:5
        WAP3'A1              5'tagcagcagattgaaagcattatg
        SEQ ID NO: 6
        FIXA1                5'gtgaactttgtagatc
2. Production of Modified (Kpn I) FIX cDNA 
The FIX cDNA (containing Kpn I sites located immediately before the start sequence and 
after the stop sequence) was generated as a PCR fragment. Fragment production protocol 
is as follows: 100 .mu.l total volume containing 200 .mu.M dNTP's, 0.5 .mu.M of each 
primer (humFIX5'KpnI and humFIX3'KpnI, as shown in Table 6), 2.5 units Pfu 
polymerase and 30 ng of plasmid template (pMCDSFIX obtained from Prof. Darryl 
Stafford, Department of Biology, University of North Carolina, Chapel Hill, N.C., USA), 
reaction mixture was subjected to 30 cycles of denaturation at 95.degree. C. for 20 sec, 
annealing at 50.degree. C. for 1 min and elongation at 75.degree. C. for 5 min 45 sec. 
After cycling, the reaction mixture was subjected to blunting with T4 DNA polymerase 
for 10 min, EDTA concentration brought up to 25 mM, heated to 65.degree. C. for 15 
min, and extracted with Phenol: Chloroform (1:1), precipitated with equal volumes of 
95% ethanol, aspirated, and suspended in H.sub.2 O. 
3. Ligation, Transformation and Sequencing 
As is shown in FIG. 10B, the plasmid designated pUCFIX containing the modified (Kpn 
I ends) FIX cDNA was produced by digestion of both pUC18 and the modified cDNA 
with Kpn I (per manufacturers instructions, Stratagene, La Jolla, Calif.) purification of 
digestion products by CHCl.sub.3 : Phenol (1:1) extraction, precipitation with equal 
volumes of 95% ethanol, aspiration and suspension in H.sub.2 O. Ligation of plasmid and 
cDNA was per manufacturers instructions (Stratagene) using 125 ng of Kpn I digested 
pUC18 and 125 ng of Kpn I digested modified cDNA. E. coli JM109 was transformed by 
electroportation using ligation mixture and plated on LB ampicillin plates. Selected 
colonies were grown up in TB ampicillin broth. Plasmid preparations from these colonies 
were analyzed by restriction enzyme digestion (Kpn I) and gel electrophoresis. The entire 
sense strand of the cDNA was sequenced and found to be correct as compared with FIXA 
sequences located in GenBank. 
4. Introduction of FIX cDNA into pWAP4 "cassette vector" to produce pWAPFIX 
As shown in FIG. 10C, both pWAP4 and pUCFIX were digested with Kpn I in separate 
reactions, subjected to gel electrophoresis and the appropriate plasmid fragments 
removed from the gel and ligated. E. coli JM109 was transformed by electroportation 
using ligation mixture and plated on LB ampicillin plates. Selected colonies were grown 
up in TB ampicillin broth. Plasmid preparations from these colonies were analyzed by 
restriction enzyme digestion (Kpn I) then gel electrophoresis. Clones positive for the 
insert were subjected to PCR analysis using primers FIXS1 and WAP3'A1 to determine 
the correct orientation of the insert. 
As shown in FIG. 10D, the insert containing WAP promoter, cDNA and 3'WAP UTR 
was released from pWAPFIX by EcoRI digestion, subjected to gel electrophoresis, 
removed from the gel and purified. This fragment was ligated with Kpn I digested pUC18 
and the reaction mixture used to transform E.coli JM109 by electroportation. After 
electroportation, cells were plated on LB ampicillin plates with picked colonies grown in 
TB ampicillin broth. Plasmids from picked colonies were purified and subjected to EcoRI 
enzyme digestion and electrophoresis. After insert confirmation, large scale purification 
was undertaken, according to methods well known to the skilled artisan. 
(B) Production of Constructs Containing the Long WAP Promoter 
Specifically, a cassette vector containing a mouse long WAP promoter, defined as a 4.1 
kb NotI-Kpn1 fragment immediately 5' to the WAP signal sequence and a 1.6 kb 
fragment of the 3' untranslated region of the WAPgene was prepared. These regulatory 
sequences do not include coding and intragenic untranslated sequences (introns) of the 
WAP gene. 
The vector designated pUCWAP6 was derived from genetic elements from the following 
plasmids as starting material: pUC18, pWAP4 and p227.6, which were provided by the 
American Red Cross. The development of pUCWAP6 is as follows: The pUC18 vector 
was cut with the enzymes EcoRI and Hind III to remove the multiple cloning site of the 
vector, blunted with exonuclease and ligated with NotI linkers. The linerarized plasmid 
was then cut with NotI and ligated. Ligation mixture was used to transform E. coli 
DH5.alpha. cells on LB ampicillin plates, picked colonies were grown in TB ampicillin 
broth, plasmids were isolated and cut with NotI then subjected to gel electrophoresis. A 
plasmid was judged to be correct and designated as pUCNotI (See FIG. 11A). The vector 
pWAP4 as described above and as described in U.S. Ser. Nos. 08/198,068 and 
08/443,184, was cut with EcoRI and the fragment containing the WAP 5' 2.6 kbp and 3' 
genetic elements were separated by gel electrophoresis and purified. The ends of the 
fragment were modified by blunting with exonuclease and NotI linkers were ligated on. 
The fragment was cut with NotI and ligated into the NotI restriction site of pUCNotI then 
used to transform E. coli DH5.alpha. cells on ampicllin plates picked colonies were 
grown in TB ampicillin broth. Isolated plasmid was verified to be correct by NotI 
digestion with the plasmid being designated pUCWAP5. The pUC WAP5 plasmid was 
subjected to KpnI digestion and a partial NotI digestion producing a fragment that 
contained the pUCNotI vector sequence flanked by the mWAP 3'UTR (See FIG. 11B). 
This fragment was ligated with the 4.1 kb 5' WAP promoter produced from digestion of 
p227.6 with NotI, KpnI and Hind III. The ligation mixture was then used to transform E. 
coli JM109 cells that were grown on LB ampicillin plates picked colonies were grown in 
TB ampicillin broth, plasmids isolated were cut with NotI, and NotI/KpnI and judged to 
be correct. The plasmid was then designated pUCWAP6 (See FIG. 11C). 
As shown in FIG. 12, the plasmid pUCWAP6FIX was produced by digestion of 
pUCWAPFIX with KpnI and isolating the FIX cDNA by gel electrophoresis. This 
fragment was inserted into the KpnI site of pUCWAP6 after KpnI digestion and both 
fragments were then subjected to ligation. The ligation mixture was then used to 
transform E. coli JM109 cells that were then plated on LB ampicillin plates. Picked 
colonics were grown in TB ampicillin broth and plasmids were isolated. Isolated 
plasmids were digested with NsiI to verify orientation of the cDNA insert. Plasmids that 
contained the insert in the correct orientation were designated pUCWAP6FIX. After inert 
confirmation, large scale purification was undertaken, according to methods well known 
to the skilled artisan. DNA was prepared for microinjection and injected into animals as 
described above and as is known by persons skilled in the art. Analysis of Factor IX 
DNA derived from the tissue of the transgenic animals and the analysis of the Factor IX 
produced in the transgenic animals are performed by methods well known to persons 
skilled in the art and as described in PCT/US98/02638, a continuation-in-part of 
provisional U.S. Pat. No. 60/037,145, which are both incorporated in their entirety by 
reference. Factor IX was expressed in transgenic animals made from the constructs 
described in the present invention. 
EXAMPLE 13 
Construction of Expression Vectors Containing a Long Mouse Whey Acid Protein 
Promoter Fragment and Fibrinogen (FIB) DNA for Expression in Transgenic Animals 
(A) Construction of Cassette Vectors 
FIB subunit chain DNAs, tissue-specific promoters, and secretion signal sequences were 
obtained from sources described above. FIB subunit chain cDNAs were cloned into a 
modified pUC 18 vector, and grown up in E. coli JM109. 
A pUC18 vector (GIBCO-BRL, Gaithersburg, Md.) was digested with HindIII+ EcoRi 
restriction endonucleases, blunted with T4 DNA polymerase in the presence of 100 mM 
dNTPs, and a Not I linker was ligated into the former HindIII-EcoRI multiple cloning 
site. This modified pUC fragment was additionally digested with Not I+ enzyme to 
remove extra (multiple copies) Notd linker sequences arising from ligation, and then 
religated and grown up in E. coli JM 109. This procedure modified the pUC18 vector by 
removing the entire multiple cloning region of pUC18 (including the Kpn I site) and 
replacing it with a Not I restriction site. The new vector was designated pUCNot1 +. 
A pUC vector containing .sup..about. 2.6 kbp of WAP 5' promoter region, .sup..about. 
1.3 kbp of WAP 3' UTR and flanking 3', but no WAP coding or intronic regions was 
constructed (designated cassette vector pUCWAP4, as described in Example 12 and as 
shown in FIG. 11A). The WAP fragment contained within the WAP4 vector contains a 
.sup..about. 2.6 kbp WAP promoter 5' region beginning at EcoRI#1 and ending at the 
translational start site of WAP which is immediately downstream of the unique Kpn I 
endonuclease restriction site. To this KpnI site was ligated a fragment of .sup..about. 1.3 
kbp of WAP UTR and flanking 3' sequence. This WAP 3' DNA included the region from 
immediately downstream of the WAP stop codon down to the EcoRI#2 site. The WAP 
fragment contained in WAP4 was excised from the pUC vector using EcoRI, and then 
blunted, and NotI linkers were added, further trimmed by NotI digestion, and ligated into 
the pUCNotI+ plasmid which had been linearized with NotI restriction endonuclease. The 
resulting plasmid was designated pUCWAP5 (see FIG. 13). 
(2) Amplification by PCR of Fibrinogen Subunit Chain cDNAs 
The DNA sequences encoding the A.alpha., B.beta., and .gamma. chains for human 
fibrinogen (hFIB) are known and disclosed. Fibrinogen cDNA sequences encoding the 
human fibrinogen A.alpha., B.beta., and .gamma. chains are known and published. See, 
e.g. Rixon et al., Biochemistry 22, 3237-3244 (1983), Chung et al., Biocehmistry 22, 
3244-3250 (1983) and Chung et al., Biocehmistry 22, 3250-3256 (1983). The genomic 
DNA sequences encoding the human fibrinogen A.alpha., B.beta., and .gamma. chains 
are known and published. See, e.g. Chung et al., Adv. Exp. Med. Biol. 281, 39-48 (1990). 
Each of the cDNAs for A.alpha., B.beta., and .gamma. chains for human fibrinogen were 
individually modified and amplified by polymerase chain reaction (PCR) to create KpnI 
endonuclease restriction sites on their 5' and 3' ends. The 5' KpnI site was engineered by 
PCR using the primers [containing the 6 base sequence (GGTACC shown underlined in 
Table 7)] that immediately flanks the ATG start codon in the cDNAs of A.alpha., B.beta., 
and .gamma. chains for hFIB. After amplification, the ends of the extension using PCR 
products were blunted by T4-polymerase (in the presence of 
deoxynucleosidetriphosphates to inhibit processive exonuclease activity. In a similar 
fashion, a KpnI site was engineered by site modification into the 6 base sequence 
GGTACC shown underlined in Table 7 immediately flanking the stop sequence in the 3' 
UTR of each cDNA for A.alpha., B.beta., and .gamma. chains for hFIB. The complement 
of the stop sequences is shown in bold in the 3' primers in Table 7. 
                             TABLE 7
               Oligonucleotides for Amplifying FIB
                      Subunit Chain cDNA
            Seq. ID No: 7
            A.alpha. 5' GCTAGGTACCATGTTTTCCATGAGGATCGT
            Seq. ID No: 8
            A.alpha. 3' CAGTGGTACCCTAGACAGGGCGAGATTTAG
            Seq. ID No: 9
            B.beta. 5' GCTAGGTACCATGAAAAGAATGGTTTCGTG
            Seq. ID No: 10
            B.beta. 3' CAGTGGTACCCTATTGCTGTGGGAAGAAGG
            Seq. ID No: 11
            .gamma.5' GCTAGGTACCATGAGTTGGTCCTTGCACCC
            Seq. ID No: 12
            G.gamma.3' CAGTGGTACCTTAAACGTCTCCAGCCTGTT
    GGTACC = KpnI site
    ATG = start codon
    CTA and TTA = stop codon
(C) Construction of pUC Plasmids Containing Fibrinogen Subunit Chain cDNA 
The blunted PCR products of the cDNAs for the B.beta. and .gamma. chains of hFIB 
were digested with KpnI restriction endonuclease. In the case of the A.alpha. chain, the 
PCR product was blunt-end cloned into pUCNotI+ (which had been digested with NotI 
and blunted with T4 Polymerase) prior to partial KpnI digestion. This intermediate 
cloning and partial digestion step was necessary to generate intact coding fragment due to 
the presence of an internal KpnI site within the A.alpha. chain cDNA. The intact A.alpha. 
chain cDNA fragment was selected by gel electrophoresis, and cloned into the KpnI site 
at the junction between the WAP 5' promoter and WAP 3' UTR/flanking sequences 
within the pUCWAP5 plasmid. The KpnI-digested PCR products from B.beta. and 
G.gamma. chains for human fibrinogen were each directly cloned into a pUCWAP5 
plasmid at the KpnI site. Separate electroporation transformation reactions were done on 
E. coli using each of the three pUCWAP5/fibrinogen cDNA preparations, and colonies 
were picked and grown up in TB ampicillin broth. Plasmid preparations from these 
colonies were analyzed by restriction enzyme digestion and gel electrophoresis. The 
correct size and orientations were selected and one clone for each WAP-fibrinogen 
cDNA construct was sequenced at the WAP promoter 5':fibrinogen cDNA and fibrinogen 
cDNA:WAP 3' UTR and flanking junctions. Schematics summarizing the construction of 
the WAP-A.alpha. (about 5.8 kbp), -B.beta. (about 5.4 kbp), and -.gamma. (about 5.2 
kbp) cDNA plasmid and linearized transgenes for human fibrinogen are given in FIGS. 
14, 15, and 16, respectively. 
Each of the pUCWAP5-A.alpha., pUCWAP5-B.beta. and pUCWAP5-.gamma. are 
digested with KpnI and the DNA fragments encoding the A.alpha., B.beta., and .gamma. 
chains were isolated by gel electrophoresis. The plasmid pUCWAP6 as shown in FIG. 
11C was digested with KpnI as shown in FIG. 12 for the preparation of Factor IX long 
WAP constructs. Each of the fragments encoding the A.alpha., B.beta., and .gamma. 
chains was inserted into the KpnI site of pUCWAP6 after KpnI digestion and both 
fragments were then subjected to ligation. The ligation mixture was then used to 
transform E. coli JM109 cells that were then plated on LB ampicillin plates. Picked 
colonics were grown in TB ampicillin broth and plasmids were isolated. Isolated 
plasmids were digested with NsiI to verify orientation of the cDNA insert. Plasmids that 
contained the insert in the correct orientation were designated pUCWAP6-A.alpha., -
B.beta. and .gamma., respectively. After inert confirmation, large scale purification was 
undertaken, according to methods well known to the skilled artisan. DNA was prepared 
for microinjection and injected into animals as described above and as is known by 
persons skilled in the art. Analysis of hFIB DNA derived from the tissue of the transgenic 
animals and the analysis of the hFIB produced in the transgenic animals are performed by 
methods well known to persons skilled in the art and as described in U.S. Ser. Nos. 
08/443,184 and 08/198,068, which are both incorporated in their entirety by reference. 
The expression of fibrinogen in transgenic animals made from some of the constructs 
described in the present application is disclosed in Butler et al., Thrombosis and 
Haemostasis, 78(1) 537-542 (1997). 
Although the foregoing refers to particular preferred embodiments, it will be understood 
that the present invention is not so limited. It will occur to those of ordinary skill in the 
art that various modifications may be made to the disclosed embodiments and that such 
modifications are intended to be within the scope of the present invention, which is 
defined by the following claims. 
All publications and patent applications mentioned in this specification are indicative of 
the level of skill of those in the art to which the invention pertains. All publications and 
patent applications are herein incorporated by reference to the same extent as if each 
individual publication or patent application were specifically and individually indicated 
to be incorporated by reference in its entirety. 
                                 SEQUENCE LISTING
 <100> GENERAL INFORMATION:
    <160> NUMBER OF SEQ ID NOS: 12
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 1
    <211> LENGTH: 4122
    <212> TYPE: DNA
    <213> ORGANISM: WAP gene promoter fragment from the C57B/6 mouse 
strain
    <220> FEATURE:
    <221> NAME/KEY: misc_feature
    <222> LOCATION: (544)..(544)
    <223> OTHER INFORMATION: "n" is unknown
    <400> SEQUENCE:  1
    gatctctcca tctaaggacc agccatgagc cattgagcag ccacagaaaa catttactat     
60
    ttatttatct atttattata tttaaataaa cataaaatat aaacatatca atgttgttaa    
120
    tgttttattc atgtgtattt gttaatattt ataacttact aatatttatt aagacttgtc    
180
    tctgtgtgtg tgtgtgtgca tgtgtgtgtg catgtgtgag gtatacatgt gtatacaggt    
240
    gcataaagag agcgagagct ttgttctaga gttggaacta caggtagttg tgaggcaaca    
300
    gatttgaatc ctggagacaa acttggtcct ctacaagatc accaagtaat ctttacaact    
360
    gagccatctt tccaggccct gaagataatt tttaatggaa tagggggact aataattttt    
420
    caaagatttt atttatttgc attttatcgg ttctgaatat tttacctgca tgtaagtgcc    
480
    acaaaagact agaaggagga ggcaggtcct agaactggac ctagggccat cctcggctac    
540
    tatntgggct ctgggaatct agcctgcatc ttcagcaaga gcaacaagtg ctcttaacct    
600
    gttgacccat gtgtgtttat gtatcaagca cagtgagctg cttctgtaga gggtggccaa    
660
    ggcctgaaca ttctcagcag actggaacac ctaacccaat ctctacttga gggaaaactc    
720
    agggactcct cccaggcatc tcctctcaga cccaaggttg agcccaggag ctccttgccc    
780
    tgtgcctaag gagtggtaga aagaggaagt gtgggcccct tttccaaggt ggggatcaac    
840
    ttgatgctct gacccctact gtccttcaag atccacaaac actgtaaagg gtttcctggg    
900
    tacctctaaa tcacagcatg actgaaaaaa atccccctag actgtaaagg gtttcctggg    
960
    cctgtttaga aaccacttct ctatcacctg ctaattctcc acagtccctg ttccaatgga   
1020
    gaccctcctg gcaggtttct gaaggaggga gtagcaggtc aaacttctcc tctcatcaga   
1080
    ggagaggcca ggccctcctc cttctcacca aaggggctca acacctcacc ccttctcagc   
1140
    acttctgcct tctcacttaa acatggtgac cccagactct gtgccaacaa tcactccctc   
1200
    ctgggggcac ctctggaggc tgcaccccgt ccgctggacc caacacagat gggctagcta   
1260
    acgagccaca agggaacatg ccagagccac atagtgcagt agagcagcca tgcagctcgt   
1320
    acctccttgc tgttgcttag agcagccggt gccagctggg gtgtctaaca caattaccct   
1380
    tggtgctgct gagcagggga caggccaagg agctttgggg aaggagacac actgtatacg   
1440
    gatatgactg aggcatatga ggggtgtagg agagcctcag aatgagcagc aaggcctatg   
1500
    actaaggtct gacatagcac agtgacaagg atgacatgta gtcgtgactt cactgaagag   
1560
    ggagagactc tcactcagaa ttcctaagca ccatggccaa gaatggggca agctgttcat   
1620
    ccaggagcca taaagcacta caagaaagaa gcaagctcgt ggggcaggca gcctgtcctc   
1680
    ctccatcacc ctgtcctcct cttccaccct gtccactgct caggttttta gggaaaattc   
1740
    cagcacagct gaccccatag gacaaaaagt gcagtgtgtg tactaccaaa accctgggtg   
1800
    tccttttccc accctagccg agcagagttg atggggcagg aaagagccta gcatactgga   
1860
    agcacacagg ctcaagactg gcaggccaaa gaaccagaac accccagggc ataagaaccc   
1920
    catgcccctt gccgctgggc ctggtgaatt cagagtaatg tcttcattcc tagaaccttc   
1980
    tggcttcccg acctggcctg caggctctga gagatgtgtg cacctcatga actccttgtt   
2040
    cagccagggc ctctctgtcc tccctacact tccccaccac acaggaacac atgtcctcaa   
2100
    ctgaccagtg tcaccctggg cctcaaggct aggttccctt gagtactggg aacacaagaa   
2160
    tagacttctg ctctcccctc tgtccacaca gagtgcagag agcaagggtt ctggttcatg   
2220
    tcccacagtt gccccctaaa accgatgtga tatagccctc actggcctag agctcactac   
2280
    ataaacaggc tggcctgaac ccacagatct gtctgccttt gactcctact gctgggatca   
2340
    aaggtgtgag ccaccatgca acgctctgaa actgattctt tagaagctaa gaaaatgctt   
2400
    caaaatggca gtagccttgg cgtggagatg ggttagtggt taagagaact gactgctctt   
2460
    ccagagagag agagagagag agagagagag agagagagag agagagagag agctggaaga   
2520
    gggagatctg ggaagtctgc tggctttata tgctgaccat atatagtcac ctgtgtttac   
2580
    aactgttgct catcactttg aaatctcagt ggtttcctcc tttgagcctg tgtctgtaag   
2640
    ttacacagga cagtggtact ataggcaaga ataacagcca gtgggcatag gacacagagt   
2700
    gcatgggccc cagcaagatg cagagagaac agagctctgg ctcctaagac acagggcctt   
2760
    ctgggaaact caagcagcca agcaacccta gccagccctt tcctggtggc cctccttctg   
2820
    ttccagcaaa ggcggaaatg ggaacagggg tggaagcaga gcattggcag agcataggta   
2880
    tgacttagtc ttgactaaca caagcatggc agtagcctga cagtggccta aatgtgggga   
2940
    tgactgcctt agatgaggat gactgcctta gatggggatg actgccttag atggggatga   
3000
    ctgccttaga tggggatgac tgccttagat ggaacaacaa acatctatgg gcatgctgtg   
3060
    gaacactggc ccacacacgg aactgaagca ctggcaattt ccacagggca gttaaaccta   
3120
    aaagcatgct cacactcaac aggctgccgg aactcatgag acacctggaa tagacgaatg   
3180
    tagaaacaga gcagagagtt ggttgccaag gtctgggggc tcagaggaca agcaagaggc   
3240
    gcggctttcc tttggggctg gcatgaaagg aaatatcgag gttacagcct gagagggctt   
3300
    cccctgacac ttcgtattca aagaggccat gggcaccagt gaagacaaag gagtatggcc   
3360
    tgcaccacag gctggcnctg acagtcagta agcacacagt cactctgggt catcccatcc   
3420
    ccttccttgc aagagaaatc aaggaaatgt cccgagaaca atggggcaca gtgccagcag   
3480
    gacatctctt cctgcccaat gacacccttg gcacagtatg ggcccttctg ggaagttggc   
3540
    cttccaatgt gctctgcaca ggcagctcct tttcaatgta tgcccgacac tctctacatg   
3600
    gagcaagcgc ctccacactc ttagaagaat ttttagaaaa ctccagaaaa gcaccaggag   
3660
    aagtcaccct cagatgtagc ccggactcga gccttgctca aaacctcctg tcttgttttc   
3720
    tatgtgactg tacaaatttg gagctcagaa ttgcctttgt ctgtgatggg ttccaaccca   
3780
    accactcaaa gtgacacttg tcacatttgt cactgatcct atttcttctt tttctgctcc   
3840
    ttcattttct ccgctttcat aataaacaag tattactttt taagtggggg aaaaaatgac   
3900
    cacccttaca aaggactttt taaaaatggc ctccattgtg gcccttgttc ctggcagcct   
3960
    gggcctgctc tctctgtgtg gccaagaagg aagtgttgta gcccatctag agctgtgcca   
4020
    gcctcttccc ccaccccacc cccaaagtct tcctcctgtg ggtcctttaa atgcatccca   
4080
gacactcaga cagccatcag tcacttgcct gacaccggta cc                      
4122
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 2
    <211> LENGTH: 20
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  2
    gctaggtacc atgcagcgcg         
20
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 3
    <211> LENGTH: 21
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  3
    gtcaggtacc ttaagtgagc t                                     
21
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 4
    <211> LENGTH: 21
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  4
    ggataacatc actcaaagca c                                               
21
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 5
    <211> LENGTH: 24
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  5
    tagcagcaga ttgaaagcat tatg                                            
24
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 6
    <211> LENGTH: 16
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  6
    gtgaactttg tagatc                                                     
16
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 7
    <211> LENGTH: 30
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  7
    gctaggtacc atgttttcca tgaggatcgt                                      
30
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 8
    <211> LENGTH: 30
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  8
    cagtggtacc ctagacaggg cgagatttag                                      
30
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 9
    <211> LENGTH: 30
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  9
    gctaggtacc atgaaaagaa tggtttcgtg                                      
30
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 10
    <211> LENGTH: 30
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  10
    cagtggtacc ctattgctgt gggaagaagg                                      
30
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 11
    <211> LENGTH: 30
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  11
    gctaggtacc atgagttggt ccttgcaccc        
30
    <200> SEQUENCE CHARACTERISTICS:
    <210> SEQ ID NO 12
    <211> LENGTH: 30
    <212> TYPE: DNA
    <213> ORGANISM: primer
    <400> SEQUENCE:  12
    cagtggtacc ttaaacgtct ccagcctgtt                                    
30
